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Abstract 
The purpose of this study was to determine whether there is evidence to support conducting a 
larger randomized control trial (RCT) to compare the non-operative treatment of Achilles 
tendon (AT) ruptures with or without Autologous Conditioned Plasma (ACP®). Twenty-four 
patients were randomized to receive an ACP® or saline injection within seven days and 
again at two weeks post-rupture. Tendon healing was longitudinally evaluated using 
ultrasound (US) and magnetic resonance imaging (MRI). Functional and patient-reported 
quality of life measures were also assessed. A small sample size limited our ability to detect 
statistically significant differences. The mean rankings of healing were slightly higher in the 
ACP® group at most time points for MRI and US. Functional and patient-reported outcomes 
were also slightly higher in the ACP® group at most time points. The consistency of these 
preliminary results suggests that there is evidence to support conducting a larger RCT. 
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Chapter 1  
1 Introduction  
Rupture of the Achilles tendon (AT) is one of the most common tendinous injuries within 
the adult population. Throughout the last two decades, the incidence of AT rupture has 
significantly increased as a result of more adults participating in high-demand sports1–3. 
Tissue healing and regeneration in the AT is a slow process which results in a slow return 
of normal function. Management of AT ruptures can be broadly classified into operative 
and non-operative treatment, although there is considerable debate regarding which 
treatment is optimal as each has unique advantages and disadvantages. In the past, 
operative treatment has been associated with a lower risk for re-rupture at the expense of 
a higher risk of surgical and post-surgical complications, whereas non-operative 
treatment is associated with a lower risk of complications but a higher risk for re-rupture.  
However, in 2010, Willits et al4 published the results of a randomized control trial that 
reported similar functional and patient-reported outcomes, as well as similar re-rupture 
rates between operatively and non-operatively treated patients. They hypothesized that 
the similarity in re-rupture rates was attributed to the early mobilization rehabilitation 
protocol. A recent meta-analysis of the literature by Soroceanu et al (2012)5 yielded 
similar conclusions regarding re-rupture rates when the non-operative management 
included early mobilization.  
Platelet-rich plasma (PRP) is a generic term describing products that contain above-
average amounts of platelets in a small volume of plasma. PRP has been used 
increasingly for the treatment of various orthopedic injuries6. The physiological rationale 
for concentrating platelets at a site of injury is to optimize the healing environment, 
although there is no clear indication for the clinical efficacy of PRP.  
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One limitation of PRP research is the lack of standardization of the intervention, 
preparation methods and contents of the PRP. Different preparation methods yield PRP 
samples with different platelet concentrations and leukocyte concentrations. Some 
samples also require an exogenous platelet activator. To determine the most effective 
method of PRP preparation and administration, this information must be reported and 
more head to head comparisons evaluated7.  
To date, there has been one study that has examined the effectiveness of ACP® for the 
non-operative management of AT ruptures8. The results of this study did not support a 
measurable clinical or functional benefit of ACP® when compared to non-operative 
management without ACP®. The notable limitations of this study include the use of a 
retrospective control group, and an ACP® injection period spanning 14 days from the 
time of rupture. There is anecdotal evidence that suggests that earlier PRP injections (i.e. 
at the time of surgery, less than seven days post-rupture) may yield more favorable 
functional and histochemical results9–12.  This may be related to the contents of the PRP 
and because the PRP may be most effective during the inflammatory phase of tendon 
healing. One of the significant characteristics of this phase of healing is the activation of 
platelets at the site of tendon injury, which can last up to seven days post-injury13–15.  
Thus, the purpose of this randomized control trial is to determine whether ACP® 
injections within seven days post AT rupture and again at two weeks post-rupture 
demonstrate better tendon healing on imaging (i.e. ultrasound and magnetic resonance 
imaging), better functional outcomes, and more favorable patient-reported outcomes than 
patients with AT rupture who receive saline injections at the same time points. Should 
this study demonstrate that earlier ACP® injections yield more favorable outcomes, then 
a larger RCT would be warranted.  
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Chapter 2  
2 Literature Review  
2.1 Anatomy of the Achilles Tendon  
A tendon is a type of connective tissue that is interposed between muscle and bone. 
Tendons are comprised primarily of collagen (specifically type I collagen) and elastin 
embedded in a proteoglycan-water matrix, with collagen and elastin accounting for 65-
80% and 2-4% of the tendon’s dry mass, respectively16. The fibro-elastic nature of the 
tendon makes it resistant to mechanical loads, thus allowing the force generated within 
the muscle to be transmitted to bone, ultimately enabling movement about a joint16.  
The Achilles tendon (AT) is the thickest and strongest tendon in the human body17,18.  
The distal aspects of the gastrocnemius and soleus muscles merge to form the origin of 
the AT (Figure 1). The gastrocnemius is a fusiform muscle formed by medial and lateral 
heads originating from the distal femoral condyles19, and is the most superficial muscle in 
the dorsal aspect of the lower leg19,20. The soleus is deep to the gastrocnemius and can be 
described as a pennate muscle originating from a fibrous arch between the tibia and fibula 
in the middle third of the lower leg and from the posterior surface of the head of the 
fibula19,21. The gastrocnemius and soleus form the triceps surae, which acts to plantarflex 
the ankle joint via the AT20. 
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Figure 1 Calf muscles and Achilles tendon 
Medical Illustration Copyright © 2015 Nucleus Medical Media  
The average length of the AT is 15 cm, but can range from 11 to 26 cm20,22,23.  At its 
proximal origin the AT is rounded, but flattens out at the distal insertion. The mean width 
of the AT is 6.8 cm (4.5-8.6 cm) at its origin and gradually decreases distally. The AT 
inserts at the midpoint of the posterior surface of the calcaneus, with a mean width of 3.4 
cm (2.0-4.8 cm)20,23.  
2.2 Achilles Tendon Rupture  
2.2.1 Epidemiology  
Although the AT is the most commonly ruptured tendon in the body24, few studies have 
examined the epidemiology of AT ruptures. Leppilahti et al (1996)25 detailed the 
incidence of AT rupture in Oulu, Finland from 1979 to 1994. During this 16-year period, 
there were 110 ruptures. The incidence increased from two ruptures per 105 individuals 
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between 1979 to 1986, to 12 ruptures per 105 individuals between 1987-1994.The peak 
age-specific annual rupture incidence was in individuals aged 30-39 (r=0.74, p<0.001). 
The rupture ratio of males to females was 5.5:1. Additionally, 81% of ruptures occurred 
during sporting activities with 88% of those occurring during ball games.  
Similarly, Möller	  et	  al	  (1996)	  studied	  the	  incidence	  of	  AT	  rupture	  in	  Malmö,	  Sweden	  from	  1987-­‐1991.	  They	  reported	  153	  diagnosed	  cases	  during	  this	  span.	  The	  average	  annual	  age	  incidence	  per	  105	  was	  calculated	  for	  each	  10-­‐year	  age	  interval.	  The	  highest	  incidence	  was	  found	  in	  the	  30-­‐39	  year	  age	  group	  with	  an	  incidence	  of	  30.4	  per	  105	  individuals.	  There	  were	  significantly	  more	  men	  (132)	  than	  women	  (21)	  that	  were	  diagnosed	  with	  AT	  rupture.	  Sports	  injuries	  (98)	  were	  more	  common	  than	  other	  injuries	  (55),	  with	  badminton,	  soccer,	  and	  tennis	  being	  the	  sport	  most	  often	  leading	  to	  AT	  rupture.	  	  
A literature review conducted by Leppilahti & Orava (1998)1 found similar results to the 
previous study conducted by Leppilahti et al (1996)25 with respect to the average rupture 
ratio of males to female (6:1) and the age of peak incidence (30-40). Additionally, they 
found that an average of 75% of AT ruptures were sports-related, especially recreational 
sports demanding sudden acceleration and jumping. Within this group, an average of 8 to 
20% of AT ruptures occurred in elite athletes, 75% in recreational athletes, and 10 to 
12% did not take part in any sports.  
Suchak et al (2005)26 retrospectively examined the incidence of AT rupture in the North 
American population, specifically in Edmonton, Canada. They found a comparable 
incidence (8.3 ruptures per 105 individuals) to those reported in European communities 
(range 6 to 37 per 105 individuals).  The rupture ratio of males to females was 4:1, with 
the mean age of males being 40.6 years and females being 44.5 years. The 30-39 and 40-
49 year old age groups were most frequently associated with AT rupture in men and 
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women, respectively. The percentage of ruptures associated with sporting activities was 
78.6%. 
Gwynne-Jones et al (2011)27 conducted an epidemiological study in Dunedin, New 
Zealand. They found an incidence of approximately 24 per 105 individuals over an 8.5 
year period. Out of 363 AT rupture patients, 197 (54%) were males and 166 (46%) were 
females. They also found an equal gender distribution up until the age of 50, but there 
were significantly more males (73%, p=0.0007) in the age group 51-60 years. The mean 
age of males was significantly higher than females [41.2 years (SD, 9.6) vs. 37.6 years 
(SD, 9.3), p=0.0004].  The majority (78.5%) of AT ruptures occurred during sporting 
events, with 31% of these attributed to netball.  
More recently, Lantto et al (2014)28 examined the epidemiology of AT rupture over a 33 
year period in Oulu, Finland from 1979 to 2011.  There were 528 ruptures in 515 patients 
(456 male, 59 female) with a mean age of 43 years for all patients (SD 13, range 19-90). 
Sports-related injuries accounted for 70% of cases. The overall incidence increased from 
2.1 (95% CI 0.3-7.7) per 105 person-years in 1979 to 21.5 (95% CI 14.6-30.6) per 105 
person-years in 2011. For each 11-year period, the incidence of ruptures increased in all 
age groups; in the first 11-year period (1979-1989) the highest incidence was in the 40-49 
years old age group, but for the next two 11-year periods (1990-2000, 2001-2011) the 
highest incidence was in the 30-39 year old age group.  
2.2.2 Etiology  
There are two main theories advocated for the cause of, or predisposition to, AT rupture 
within the orthopaedic literature: the degenerative theory and the mechanical theory1,2. 
Several other factors have also been associated with AT rupture but with little agreement 
amongst researchers regarding definitive contributions17. These factors include poor 
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tendon vascularity17,29, iatrogenic effects from drug therapies (corticosteroids, 
fluoroquinolones, anabolic steroids)15,16,32, hyperthermia-associated rupture33, and 
underlying genetic and autoimmune conditions34,35.  
2.2.2.1 The Degenerative Theory  
The degenerative theory suggests that chronic degeneration of the tendon leads to a 
rupture without excessive loads being applied2. Arner et al (1959)36 were the first to 
report degenerative changes in patients with AT rupture, however, the histologic 
specimens were obtained more than two days post-rupture. Davidsson & Salo (1969)37 
reported marked degeneration in the AT of two patients whom were operated on the day 
of their injury, indicating that these changes had developed prior to rupture. Kannus & 
Jozsa (1991)38 suggested that degenerative changes are common in the tendons of people 
greater than 35 years of age, and that these changes can be associated with spontaneous 
rupture. Additionally, failure of the extracellular matrix has been proposed to lead to 
intratendinous degeneration. Jozsa et al (1989)39 observed fibronectin on the torn surfaces 
of ruptured ATs. Fibronectin is normally located in basement membranes, and binds 
more readily to denatured collagen than to normal collagen, indicating pre-existing 
collagen denaturation40. 
2.2.2.2 The Mechanical Theory  
According to McMaster (1933)41, a healthy tendon would not rupture even when 
subjected to a substantial strain. Barfred (1971)1,42, however, noted that McMaster’s 
experiment involved applying straight traction to the tendon which would ultimately 
distribute the strain equally throughout the muscle-tendon-bone complex rather than to 
the tendon itself. Oblique loads or traction during maximal muscle contraction when the 
tendon length is initially short yields the highest risk of rupture concentrated at the 
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tendon42.  These circumstances are likely common in many athletic movements requiring 
a rapid push-off.  
It has been demonstrated that participation in sports plays a significant role in the 
development of AT problems43. Structural disturbances in lower leg mechanics from 
overtraining, functional overpronation, and gastrocnemius-soleus insufficiency has been 
proposed to lead to AT injury. Additionally, repeated microtrauma resulting from 
eccentric loading of a fatigued muscle may also play an important role in tendon injury44. 
Tendon rupture is ultimately a consequence of multiple micro-ruptures which lead to 
failure of the tendon after reaching a critical point45. 
Inglis and Sculco (1981)46 hypothesized that malfunction of the proprioceptive inhibitory 
mechanism which prevents excessive or uncoordinated muscle contractions could cause 
rupture of an otherwise normal tendon. They further proposed that this mechanism 
explains why athletes who return to or begin training after a period of inactivity are at 
greater risk for a rupture.  
2.2.3 Mechanism of Injury  
Arner & Lindholm47 were first to describe the three main categories of indirect trauma 
resulting in AT rupture. The first category (53% of ruptures in their series) involved 
pushing-off with the weight-bearing forefoot while extending the knee, as in a ‘sprint-
start’ or jump initiation. The second category (17% of ruptures) involved a sudden, 
unexpected dorsiflexion of the ankle. The third category (10% of ruptures) was violent 
dorsiflexion of a plantarflexed foot, as would occur when falling from a height. In all of 
these mechanisms, traumatic rupture occurs because the force exerted on the rapidly 
loaded tendon exceeds the tendon’s tensile strength48. 
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2.2.4 Clinical Presentation  
Patients with acute AT rupture typically describe the sensation of being hit in the 
posterior aspect of the lower leg at the time of rupture. Some patients report an audible 
‘snap’.  This is followed by pain, an inability to bear weight, an inability to plantar-flex 
the ankle, weakness or stiffness in the calf muscle of the affected ankle. Physical 
examination may reveal edema and bruising; a palpable gap may be felt along the tendon 
at the site of the rupture, depending on the amount of swelling present. The calf-squeeze 
test (Thompson test or Simmonds test) and the Knee-flexion (Matles) test are the most 
sensitive (0.96, 0.88 respectively) and specific (0.93, 0.85 respectively) tests for 
diagnosing AT rupture49.  
2.2.4.1 Calf-Squeeze (Thompson or Simmonds) Test  
The calf-squeeze test is performed with the patient prone on the examination table and 
the ankles clear over the edge of the table. The examiner squeezes the bulk of the calf 
muscle, deforming the soleus muscle and causing the overlying Achilles tendon to bow 
away from the tibia, resulting in plantarflexion of the ankle if the tendon is intact50. 
Limited or no movement of the ankle compared to the contralateral (i.e. uninjured) ankle 
indicates a rupture51.  
2.2.4.2 Knee Flexion (Matles) Test  
Also lying prone on the examination table, patients are asked to actively flex their knees 
to 90 degrees. During flexion, if the injured foot falls into neutral or dorsiflexion, an AT 
rupture can be diagnosed52. 
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2.2.4.3 Imaging 
Although clinical examination is generally sufficient for a diagnosis of a full AT rupture, 
some researchers have reported that more than 20% of full ruptures can be missed 
clinically upon initial presentation 53–55. The ability to correctly distinguish a full versus a 
partial rupture or tendinopathy has clinical implications that directly affect patient care, 
as the treatment algorithm can be different for each diagnosis56. In a study evaluating the 
ultrasonographic differentiation of full versus partial Achilles tendon ruptures, Hartgerink 
et al (2001)56 reported the following results: sensitivity=100%; specificity=83%; 
accuracy=92%; positive predictive value=88%; negative predictive value=100%. 
Evidently, imaging can be a useful adjunct to clinical evaluation and diagnosis. 
2.2.4.3.1 Ultrasonography  
Ultrasonography (US) is a medical imaging technique that uses high-frequency sound 
waves and their echoes to produce a two-dimensional image of anatomical structures57. 
Superficial tendons, such as the AT, are well suited to evaluation by high-resolution real-
time US58. US is a rapid, reliable, and cost-effective means of evaluating the integrity of 
the AT56,59,60. US has been used increasingly in the investigation of the AT, from the 
diagnosis of ruptures and tendinopathy to post-treatment followup56,61–63.  
Ultrasonography of the AT with linear probes produces a dynamic and panaroamic image 
of the tendon64. The AT is composed of longitudinally arranged collagen bundles, which 
reflect the ultrasound beam. A normal AT appears as a hypoechogenic, ribbon-like image 
that is contained within two hyperechogenic bands (Figure 2)65. Tendon fascicles appear 
as alternate hypoechogenic and hyperechogenic bands that are separated when the tendon 
is relaxed and more compact when the tendon is strained66. The number of fascicles that 
are visible with US closely correlates with the frequency of the ultrasound probe used61. 
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Figure 2 Ultrasonographic appearance of a normal Achilles tendon 
Reproduced with permission of W.B./Saunders Co. in the format thesis/dissertation via Copyright 
Clearance Centre (order detail ID: 68044510) 
When the AT is ruptured, the site of rupture will appear as an “acoustic vacuum,” which 
represents a gap in the tendon, with irregular edges on the ultrasonography image67,68  
and possible hypoechoic fluid distension of the synovial sheath69 (Figure 3)56. Partial 
tears appear as abnormal hypoechoic or anechoic clefts typically within an enlarged 
tendon surrounded by anechoic or hypoechoic fluid69. In cases of diagnostic uncertainty, 
dynamic evaluation of the tendon during dorsi- and plantar-flexion movements can aid in 
detecting tendon discontinuity, which indicates full rupture70.   
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Figure 3 Ultrasonographic appearance of a ruptured Achilles tendon 
Reproduced with permission from Hartgerink, Fessell, Jacobson, et al (2001); Radiological Society of 
North America; 220; 406-412 
2.2.4.3.2 Magnetic Resonance Imaging  
A magnetic resonance imaging (MRI) scan is a diagnostic imaging procedure whereby 
powerful magnets and radio waves produce images of the internal structures of the body. 
MRI is a powerful and versatile diagnostic tool that can provide definitive diagnoses for a 
wide range of musculoskeletal pathology71. There are several factors that influence the 
quality of the images obtained, including: lack of motion during the procedure; the signal 
intensity and resolution of structures; and tissue contrast72. Different MRI sequences or 
protocols are used when evaluating different structures of interest (i.e. tendons, 
ligaments, bone, etc.) in order to optimize the intensity, resolution, and contrast of the 
images72.  
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2.3 Healing Following Achilles Tendon Rupture  
Tissue regeneration and turnover in the Achilles tendon is an extremely slow process. It 
has been demonstrated that the core of the AT are formed during skeletal growth and 
maturity, with very little regeneration thereafter73. In contrast, the periphery of the tendon 
is capable of altering its structure, composition, and mechanical properties in response to 
mechanical forces through fibroblast-mediated biomechanical signaling. The 
physiological and pathological changes associated with this process are not well 
understood74,75. 
The repair of injured tendons can generally be described in three overlapping phases: the 
inflammatory phase; the proliferative or reparative phase; and the remodeling phase14,15 
In the inflammatory phase, bleeding caused by the rupture leads to hematoma and 
subsequent activation of platelets and neutrophils, which leads to the release of growth 
factors, chemotactic factors, and vasoactive factors. These factors recruit tendon 
fibroblasts to begin collagen (type III) synthesis and deposition. This phase of healing 
generally lasts between 24 and 48 hours, but these processes can occur up to seven days 
and overlap into the next phase of healing. Approximately three days after the injury, the 
proliferative phase begins which is highlighted by increased angiogenesis and collagen 
production. Water content and glycosaminoglycan concentration are high during this 
time. After approximately six weeks, the remodeling phase begins and can last for several 
years. This phase is characterized by decreased cellularity, decreased type III collagen 
synthesis, and a gradual increase in type I collagen synthesis. The repaired tissue changes 
to fibrous tissue, which again changes to scar-like tendon tissue after 10 weeks. During 
the latter stages of remodeling, covalent bonding between collagen fibres increases which 
results in higher stiffness and tensile strength in the repaired tissue14,15,74–77.  
14 
 
 
 
 
 
2.3.1 Clinical Assessment of Healing 
The clinical assessment of AT healing uses many of the same criteria as the clinical 
diagnosis of AT rupture (i.e. palpation of the tendon, Thompson’s test, Matles test). 
Additionally, there are functional criteria that clinicians use to subjectively assess the 
integrity and healing of the tendon such as the unilateral heel-rise test, active and passive 
range of motion, and tendon elongation measures. During the heel-rise test, the patient is 
asked to perform a heel-rise on their uninjured leg to establish a baseline, followed by a 
heel-rise on their injured leg. A successful heel-rise is acknowledged if the heel can be 
lifted at least 2 cm off of the ground with an extended knee. The heel-rise appears to 
reflect the general level of subjective and objective healing in AT rupture patients78. 
Tendon elongation can be assessed in the Matles test position, where if the injured foot 
falls into neutral or dorsiflexion it is indicative of tendon elongation52. Passive range of 
motion can also be assessed in this position.  
2.3.2 Using Imaging to Assess Tendon Healing  
2.3.2.1 Ultrasound 
US is frequently used to diagnose tendon injuries, but is less commonly used to assess the 
state of healing in these structures79. US studies that examined tendon structure after 
rupture or tears of the Achilles tendon have qualitatively assessed several criteria, 
including: the appearance of torn tendon ends; focal areas of echogenicity; peritendinous 
reactions, such as edema or effusion; hyperemia via colour Doppler US; the presence of 
calcifications; and the overall appearance of the tendon with respect to thickening or 
thinning56,58,61,68,80,81. Several of these criteria are associated with other tendon 
pathologies, such as tendinitis or tendinosis79,80,82. Additionally, these criteria have not 
been consistently correlated with clinical or functional parameters81,83. The relative 
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importance or contribution of each of these criteria to tendon healing after rupture is 
therefore unknown. 
Hollenberg et al (2000)61 described the gray-scale and colour Doppler sonographic 
appearance of healed AT ruptures that have been treated non-operatively. A total of 11 
patients were evaluated at baseline and at a mean of 22.4 (range 7-38) months post-
injury, when the treating physician considered the patient clinically healed. Distortion of 
the fibrillar architecture decreased markedly in all follow-up scans. In only 4 of 11 cases 
were the tendon ends still visible at the torn rupture site (Figure 4)61. Gaps between the 
torn tendon ends seen acutely in three patients were resolved upon tendon healing. 
Hematomas were present in all initial scans, and were resolved in all but one follow-up 
scan. The healed rupture sites were notable for mild residual distortion of the normal 
fibrillar architecture, slight anterior bulging or irregularity of the healed tendon, and a 
hypoechoic area at the site of prior rupture (Figure 5, Figure 6)61. The authors concluded 
that the healed AT after rupture has a different appearance than a normal AT, but that 
predictions of the appearance the healed tendon could not be made based on the 
appearance of the initial ruptured tendon.   
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Figure 4 Follow-up scan at 29 months demonstrating a healed tendon with resolution of 
the hematoma (arrows). The overlapping healed ends remain visible 
Reproduced with permission of Springer-Verlag in the format thesis/dissertation via Copyright Clearance 
Center (order detail ID: 67331498) 
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Figure 5 Follow-up scan at 15 months demonstrating a healed tendon with no 
discernable gap. The hypoechoic band (white arrows) and the slight bulge along the 
anterior margin of the tendon (black arrows) define the site of prior injury. There is mild 
residual distortion of the normal fibrillar architecture  
Reproduced with permission of Springer-Verlag in the format thesis/dissertation via Copyright Clearance 
Center (order detail ID: 67331498) 
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Figure 6 Follow-up scan at nine months demonstrating the healed tendon with a subtle 
hypoechoic band indicating the site of previous rupture (white arrows). Note the irregular 
contour along the anterior tendon (black arrows) 
Reproduced with permission of Springer-Verlag in the format thesis/dissertation via Copyright Clearance 
Center (order detail ID: 67331498) 
Möller et al (2002)81 serially evaluated the AT at 6, 12, and 24 months after complete 
rupture in patients that were randomized to operative and non-operative treatment. Edema 
and tendon defects were a common finding at six months, but were detected with less 
frequency after one year. Tendon thickening was noted in 100% of patients at 6 and 12 
months, and a transition from a generalized thickness to a fusiform thickness was also 
noted between these time points. A heterogeneous echogenicity pattern was present in 
100% of patients at six months, and 97% of patients at one year. This is consistent with 
the US findings of Rupp et al (1995)84, who found persistent heterogeneity from 2 to 19 
years after surgical repair in 56 of 60 patients. The authors of this study concluded no 
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significant difference in the number of positive imaging findings between operatively- 
and non-operatively treated patients. Furthermore, there was no correlation between the 
US imaging outcomes and the clinical and functional outcomes of the patients. A 
significant limitation of this study is that there was no baseline US images of the tendons 
which prevents documentation of any changes in appearance between injury and six 
months post-injury.  
2.3.2.2 Magnetic Resonance Imaging  
On MRI, a normal AT is generally low signal intensity on all pulse sequences. Some 
normal ATs may have slightly increased signal intensity near its calcaneal insertion as a 
result of non-tendinous fatty material interposed between the tendon fibers as it widens. 
There is a solid vertical line of high signal intensity in the mid-substance of many normal 
ATs, which likely represents the gastrocsoleus complex and should not be mistaken for 
pathology85.  
The first sign of tendon abnormality on MRI is often an increase in signal intensity, 
which could represent a combination of fluid, hematoma, partial tears, or tendon lesions. 
Complete rupture of the AT appears as a focal disruption with absence of the tendon 
fibers for variable distances85 (Figure 7)86. Healing tendons are characterized by having 
diffusely abnormal signal intensity and tendon thickening on most MRI sequences. From 
an imaging standpoint, a tendon can be considered healed when the tendon is 
satisfactorily aligned without a gap87. 
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Figure 7 Full thickness tear of the Achilles tendon (T1-weighted sagital MRI). There is 
discontinuity of the tendon with retraction of the proximal portion (red arrow). The distal 
tendon is tendinopathic and appears thickened and of increased signal intensity (white 
arrow). 
Reproduced with permission of BIR in the format republish in a thesis/dissertation via Copyright Clearance 
Center (order detail ID: 67464872) 
Karjalainen et al (1997)88 examined MR images of 21 consecutively recruited patients 
who underwent surgical repair after AT rupture. Images were obtained at 3, 6, 12, and 24 
weeks post-surgery. Clinical and functional evaluation occurred at the same time points. 
An intratendinous area of increased signal intensity (intermediate signal intensity, n=9; 
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high signal intensity, n=10) was observed in 19 of 21 tendons at three months post-
rupture on proton density- and T2-weighted images. The three patients with the largest 
tendon lesions at three months on MRI had clinically poor outcomes at three months. 
Furthermore, patients with an abnormal gait pattern at three months (n=5) had 
significantly larger intratendinous lesions than patients who could walk normally 
(p=0.03). In all patients, the cross-sectional area of the healing AT showed the largest 
increase between 6 weeks and 12 weeks post-surgery. Of the nine patients who had 
intermediate signal intensity lesion at three months, only one patient had a lesion present 
at six months. Of the ten patients who had areas of high signal intensity at six months, 
nine still had areas of increased signal intensity but were all reduced in size. The authors 
concluded that MRI provides a precise valuable tool to evaluate the post-surgical internal 
structure of the AT. A potential limitation of this study is the use of the 0.1 T MRI 
scanner, which would yield less contrast and detail in anatomic structures and areas of 
increased signal intensity versus the conventional 1.5 T MRI scanners used in the present 
study.  
Fujikawa et al (2007)89 examined the MRI features of normal AT healing, specifically 
with respect to the residual gap, in 30 patients who underwent percutaneous repair after 
AT rupture. AT contour and contrast enhancement at the rupture site was also assessed. 
Images were obtained approximately 4, 8, and 12 weeks post-surgery. A residual gap was 
found in 100%, 80%, 0% of the tendons on T1-weighted images and 90%, 100%, and 
100% of the T2-weighted images at 4, 8, and 12 weeks, respectively. At eight weeks 
post-surgery, palpation of the tendon by the clinician did not confirm the presence of a 
gap despite the tendon gap appearing on MR images. The authors hypothesized that the 
original gap at the rupture site may have been filled with granulation tissue at eight 
weeks, but mature fibrous tissue is likely absent. This suggests that palpation of the AT 
may not be an accurate reference standard for assessing tendon fusion. Intratendinous 
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enhancement (i.e. abnormal signal intensity) was present in 100%, 73%, and 7% of the 
tendons at 4, 8, and 12 weeks post-surgery. The authors concluded that the tendon gap 
visible on MR images can be expected to disappear approximately 12 weeks post-
surgery, and that the time-course of the MRI features of the AT after percutaneous repair 
can be considered to reflect normal healing.  
2.3.2.3 Ultrasound Versus MRI in Assessing Healing of Tendon 
Injuries  
Both MRI and US are well-suited to tendon imaging and evaluation, but MRI has been 
considered the gold standard because of its ability to provide a broader anatomic 
overview and excellent soft tissue contrast90. However, US is a more rapidly performed 
examination, has greater spatial resolution than MRI, and allows for the dynamic 
evaluation of the tendon. Furthermore, the advent of US extended-field-of-view imaging 
allows an image of the entire length of the tendon to be obtained, similar to MRI’s ability 
to display a large anatomic region. It has been proposed90 that US should best be 
considered a focused examination that concentrates on a distinct area of clinical suspicion 
of pathology, whereas MRI can provide a global assessment of a region of concern.   
Several studies that have used both US and MRI to assess various tendon abnormalities 
have found comparably high levels of accuracy with both modalities56,59,91–94. A recent 
meta-analysis95 of 65 studies comparing MRI, US, and MR arthrogram of rotator cuff 
tendon tears found that MRI and US were grossly comparable in both sensitivity (85.5% 
versus 85.1%, respectively; 95% CI=83.7% to 87.3% versus 83.5% to 86.7%, 
respectively) and specificity (90.4% versus 92%, respectively; 95% CI=89.2% to 91.6% 
versus 90.8% to 93.2%, respectively). These results, combined with the lower cost and 
testing duration, suggest that US may be the most cost-effective method of screening for 
rotator cuff tendon tears. With respect to the longitudinal assessment of tendon healing, 
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however, Connell et al (2004)94 found that MRI was more sensitive than US to follow-up 
imaging of healing hamstring tendons. To our knowledge, there have been no studies that 
have longitudinally evaluated the healing AT using both US and MRI. 
2.4 Treatment of Achilles Tendon Rupture  
AT rupture can be managed by both operative and non-operative strategies, although 
there is controversy as to which is the optimal treatment. The reason for this controversy 
is that each treatment has unique advantages and disadvantages. Specifically, operative 
treatment has been associated with a lower risk for re-rupture but a higher risk for 
complications (deep infection, deep vein thrombosis, extreme tendon lengthening, scar 
adhesion, sensibility disturbance), whereas non-operative treatment has previously been 
associated with a higher risk for re-rupture but lower risk for complications3,96,97. 
However, there is recent evidence to suggest that the differing rehabilitation protocols 
between operative and non-operative management can significantly affect re-rupture rate. 
When accelerated functional rehabilitation is employed, similar re-rupture rates are 
evident between operative and non-operative treatment5,98–103. There is little consensus 
regarding differences in functional recovery between operative and non-operative 
treatment, primarily due to inconsistencies in how this is assessed96.  
2.4.1 Operative Treatment  
Operative treatment options for AT rupture include open, minimally invasive, and 
percutaneous repair104. There are several open surgical techniques, but there is no 
evidence that adequately demonstrates the superiority of one method over another. Open 
surgery involves passing heavy, non-absorbable sutures through each stump of the 
tendon105. Evidence suggests that the strength of the repair is directly proportional to the 
number of strands that cross the repair site106. Percutaneous repair involves using stab 
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wounds to pass suture through the tendon. This technique minimizes the risk of 
complications associated with open surgical repair but increases the risk for sural nerve 
injury107,108.  
A recent systematic review conducted by Del Buono et al (2014) compared minimally 
invasive (including percutaneous repair) and open surgical techniques for treatment of 
AT rupture. They found that minimally invasive surgery yields a lower rate of 
complications (re-rupture, deep infections, deep vein thrombosis, and scar adhesion), than 
open surgery, with comparable functional outcomes (range-of-motion, strength, return to 
work time), clinical outcomes (pain, calf-circumference) and patient-reported outcomes 
(AOFAS scale). It was also noted that minimally invasive surgery is less expensive, less 
time-demanding, and more cosmetically appealing than open repair but future research 
should address the minimization of iatrogenic complications to the sural nerve during 
percutaneous repair.  
2.4.2 Non-Operative Treatment  
Surgical and post-surgical complications have been the primary reason behind the 
continued focus on non-operative management of AT ruptures. Traditionally, non-
operative treatment consisted of immobilized casting of the lower extremity for eight 
weeks, followed by a standardized rehabilitation protocol. Reports of decreased range of 
motion, muscle atrophy, and loss of proprioception associated with immobilization109 
have recently challenged this approach. Instead, early dynamic mobilization and weight-
bearing with removable below-knee orthoses has become increasingly advocated, as it 
has been suggested that this can reduce the high risk for re-rupture associated with non-
operative treatment5,98,110.  
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2.4.3 Operative vs. Non-Operative Treatment: A Review of the 
Literature  
A meta-analysis conducted by Bhandari et al (2002)111 reviewed articles comparing 
operative versus non-operative treatment of AT ruptures in the Medline, Grateful Med, 
and Cochrane databases from 1969 to 2001. The primary outcome of interest was re-
rupture rate, and secondary outcomes included deep infection rates, return to normal 
function, and spontaneous complaints. Three investigators independently reviewed 
abstracts and graded study quality. Of 273 citations initially identified, six met all 
eligibility criteria (n=448 patients). Pooled analysis revealed that surgical repair 
significantly reduced the risk of re-rupture when compared with non-operative treatment 
(3.1% versus 13%, respectively; RR=0.32; 95% CI=0.14 to 0.71; p=0.005). Five studies 
provided information on infection rates (n=421 patients) and it was demonstrated that 
infections only occurred in surgically treated patients (4.7%; range 4% to >20%). The 
relative risk (RR) of infection with surgical repair was 4.6 times greater than the cast 
treatment (95% CI 1.2 to 17.8; p=0.03). There was no significant difference in return to 
normal function and spontaneous complaints. The authors could not provide a strong 
recommendation for surgery based on these results.  
Khan et al (2005)97 meta-analyzed all randomized, controlled trials (RCTs) comparing 
operative and non-operative methods for the treatment of AT rupture. The databases 
searched included in their search were Embase, CINAHL, and Medline. The outcomes of 
interest were re-rupture and treatment complications as these were the only consistently 
reported outcomes that were conducive to meta-analysis. Four reviewers independently 
assessed all trials and assigned study-strength scores based on methodological rigor. Of 
the 36 articles identified with their search strategy, 24 were excluded due to retrospective 
study design, inadequate randomization, and insufficient information. The pooled re-
rupture rate for operative treatment versus non-operative treatment was 3.5% (6/173) and 
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12.6% (23/183), respectively (RR=0.27; 95% CI=0.11 to 0.64). With respect to treatment 
complications (infection, scar adhesion, disturbed skin sensibility) operative treatment 
was associated with a higher risk compared to non-operative treatment (34.1% versus 
2.7%, respectively; RR=10.60; 95% CI=4.82 to 23.28). The authors noted that future 
prospective, randomized studies should include larger samples, full reporting of 
outcomes, and blinded assessors in order for more accurate meta-analysis.  
More recently, Jiang et al (2012)96 conducted a meta-analysis comparing operative versus 
non-operative management of AT rupture. Two authors searched six electronic databases 
(Medline, Embase, Clinical Ovid, BIOSIS, and Cochrane registry of controlled trials) for 
RCTs between 1980 and 2011. Ultimately, ten trials were recruited for meta-analysis 
(n=894 patients). The modified Jadad scale was used to assess methodological quality, 
with eight studies being deemed good or excellent. The primary outcomes of interest 
were incidences of re-rupture and complications other than re-rupture. Secondary 
outcomes included the number of patients who returned to pre-injury sports, mean time 
for sick leave, and results for subgroup analysis (scar adhesion, superficial infection, deep 
vein thrombosis, sensibility disturbance). The results of the meta-analysis revealed that 
the operative group had significantly lower re-rupture rate compared to the non-operative 
group (4.31% versus 9.71%, respectively; RR=0.44; 95% CI=0.26 to 0.74; p=0.002). The 
operative group demonstrated significantly higher complication rates than the non-
operative group (26.6% versus 7.19%, respectively; RR=4.07; 95% CI=1.56-10.67; 
p=0.004). The mean time for sick leave was shorter following operative treatment than 
non-operative treatment (MD=-23.75; 95% CI=-41.6 to -5.89; p=0.009). There was no 
significant difference between the two methods in the number of patients who returned to 
pre-injury sports. Significant differences were found in favour of the non-operative group 
with respect to scar adhesion (RR=11.76; 95% CI=4.64 to 29.80; p<0.00001), superficial 
infection (RR=4.43; 95% CI=0.97 to 20.23; p=0.05), and sensibility disturbance 
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(RR=7.53; 95% CI=2.55 to 22.18; p=0.0003). There were no significant differences 
regarding deep infection or extreme Achilles tendon lengthening. Functional assessment 
could not be assessed in this meta-analysis due to a lack of standardized assessment 
systems. A significant limitation of this meta-analysis is that the authors did not 
separately analyze studies that used immobilization versus those that used early 
mobilization, which is an important distinction since early mobilization has been shown 
to equalize outcomes4,5 
Soroceanu et al (2012)5 conducted a meta-analysis of RCTs comparing operative versus 
non-operative treatment of AT rupture. Two independent reviewers screened 615 
abstracts within the most commonly used medical databases (Cochrane, Medline, Web of 
Science, and Embase) and was the first meta-analysis to include foreign language papers. 
Ten studies were used for meta-analysis (n=826 patients). The main outcomes of interest 
were re-rupture rate and complications other than re-rupture (infection, skin and tendon 
necrosis, fistulas, scar adhesion, sural nerve damage, decreased ankle motion, deep vein 
thrombosis, and pulmonary embolus). Meta-analysis revealed that if functional 
rehabilitation with early range-of-motion was employed, there was no significant 
difference in re-rupture rate between operative and non-operative management 
(RD=1.7%; p=0.45). However, if the non-operative treatment protocol involved 
prolonged immobilization the absolute risk reduction (ARR) in the re-rupture risk was 
8.8% in favour of the surgical intervention (p=0.001). With respect to other 
complications, meta-analysis revealed that the risk difference (RD) was 15.8% in favour 
of non-surgical treatment (p=0.016). The authors of this trial suggested that non-surgical 
management is equivalent to surgical management with regard to re-rupture rate when 
functional rehabilitation with early range-of-motion is employed.  
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2.5 Rehabilitation: Immobilization versus Early 
 Mobilization  
Over the past decade, rehabilitation has shifted from immobilizing management towards 
early mobilization112. The concept of mobilization can be further divided into: controlled 
early motion, controlled early weight-bearing, or a combination of both. Controlled early 
motion can be achieved with the use of a dynamic brace which permits movement of the 
ankle, or using a removable brace and instructing patients to periodically remove the 
brace and perform ankle exercises75. There are varying descriptions of controlled early 
weight-bearing protocols, however, they generally involve functional bracing of the ankle 
in an equinus position and weight-bearing immediately post-rupture.   
There are several physiological and biomechanical factors that explain the benefits of 
early mobilization instead of immobilization for rehabilitation protocols113. Compared to 
immobilization, early mobilization will: increase blood and lymphatic flow to aid in 
healing114–117; produce tension to stimulate tissue repair for faster healing117–119; produce 
tension to improve tissue alignment during healing120–122; limit connective tissue 
fibrosis119–121,123,124; preserve coordination caused by neuromuscular activation from 
exercise and movement125,126; preserve ROM to avoid or minimize joint fibrosis120,121,127; 
maintain proprioceptive functions123,124; produce quicker recovery and return to 
activity114,121,123,127. However, in situations where there are severe open wounds or 
fractures associated with muscle, tendon, or ligament injuries then immobilization may 
be necessary113. 
2.5.1 Controlled Early Motion  
Cetti et al (1994)99 prospectively randomized 60 patients who underwent operative repair 
of AT rupture to be placed in a new mobile cast (n=30) or a rigid below-knee 
immobilizing cast (n=30). The mobile cast was constructed such that to allow motion and 
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weight-bearing as-tolerated during the casting period. All patients had their casts 
removed at six weeks post-rupture. All patients in the rigid cast group reported painful 
edema of the injured leg daily during the casting period; there were no such reports in the 
mobile cast group. Twenty-three patients (77%) thought that the mobile cast was 
excellent, and six patients (20%) thought that the rigid cast was excellent (p<0.00005). 
Patients in the rigid cast group had significantly greater calf muscle atrophy upon 
removal of the cast compared to the mobile cast group (28.7 mm; range = 10-45 mm 
versus 18 mm; range 8-30 mm, respectively; p=0.0019). Upon removal of the cast at six 
weeks patients in the mobile cast group had significantly greater active range-of-motion 
in the ankle compared to the rigid cast group (54.3°; range 30° dorsiflexion to 70° plantar 
flexion versus 29.5°; range 5° to 60° plantar flexion, respectively; p<0.00001). Ankle 
mobility remained significantly greater in the mobile cast group at six months and one 
year (p<0.01). With respect to plantar flexion calf strength, the mobile cast group was 
significantly stronger at three months, six months, and one year post rupture (p<0.01). 
There was no statistically significant difference in re-rupture rate between the mobile cast 
group and rigid cast group. The results of this study suggest early mobilization can lead 
to favorable outcomes with respect to pain, range of motion, and strength compared to 
immobilization.  
Mortensen et al (1999)100 conducted a randomized control trial comparing early restricted 
motion of the ankle (n=36) versus conventional cast immobilization (n=35) in post-
operative AT rupture patients. Early restricted motion was accomplished by bracing the 
patients in an equinus position (30 degrees plantar flexion) with an elastic band that 
permits active dorsiflexion to neutral positioning. The immobilization group was casted 
with their ankle in the equinus position. Both groups were in their respective braces for 
six weeks post-surgery. The early motion group had significantly greater range of motion 
than the immobilizing group upon removal of the brace/cast (p<0.001) and at 12 weeks 
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(p<0.05) post-surgery. There were no differences between groups at the final clinical 
assessment, which ranged from 12 to 24 months post-surgery. There were no significant 
differences between groups regarding atrophy of calf muscles. The early motion group 
had significantly better outcomes with respect to subjective result of rehabilitation 
(p<0.05), scar-adhesion complications (p<0.01), earlier time to resume sports (p<0.001), 
and earlier time to return to pre-injury sport status (p<0.001). There was one re-rupture in 
the early motion group, and two in the immobilizing group. The authors concluded that 
early motion appears to shorten the rehabilitation period while posing no additional 
adverse risks, suggesting that larger studies are warranted to confirm these findings.  
A randomized control trial by Kangas et al (2003)101 compared early functional treatment 
(n=25) versus cast immobilization (n=25) in post-operative AT rupture rehabilitation. 
Early functional treatment involved movement of the ankle from active plantar flexion 
and active dorsiflexion to neutral while in a brace for six weeks post-surgery, whereas 
immobilized patients’ ankles were fixed at neutral for six weeks. The isokinetic calf 
muscle strength scores were excellent in 56%, good in 32%, fair in 8%, and poor in 4% 
of the patients in the early functional treatment group and excellent in 29%, good in 50%, 
and fair in 21% of the immobilized patients. There were no significant differences with 
respect to pain, stiffness, subjective calf muscle weakness, or footwear restrictions 
between groups. There was one re-rupture in the early functional treatment group and two 
in the immobilization group. The authors advocated the use of early functional treatment 
due to the potential for slightly better strength outcomes while obtaining similar results in 
all other functional and subjective outcomes.  
2.5.2 Controlled Early Weight-Bearing  
Suchak et al (2008)102 prospectively randomized post-operative AT rupture patients to a 
rehabilitation protocol that included early weight bearing (n=55) or non-weight bearing 
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(n=55). Early weight bearing commenced at two weeks post-surgery, whereas the non-
weight bearing group was immobilized and non-weight bearing for six weeks post-
surgery. At six weeks, the early weight bearing group had significantly higher scores on 
the RAND-36 domains of physical functioning, social functioning, role-emotional, and 
vitality scores (p<0.05). Additionally, patients in the early weight bearing group reported 
fewer limitations of daily activities at six weeks (p<0.001). There were no significant 
differences between groups at six months. The authors concluded that early weight 
bearing improves the patients’ quality of life in the early post-operative period with no 
detrimental effect on long-term recovery.  
2.5.3 Controlled Early Motion and Weight-Bearing 
Saleh et al (1992)128 conducted a RCT to compare the effects of early motion and weight 
bearing (i.e. early mobilization) versus cast immobilization in the non-operative 
management of patients with AT rupture. Patients randomized to the early mobilization 
group were placed in a cast for three weeks followed by controlled movement in a 
Sheffield splint for three to eight weeks. Those in the immobilization group wore a full-
leg cast with for four weeks followed by four weeks in a below-knee cast, with weight 
bearing permitted during the final two weeks. Patients in the early mobilization group had 
significantly greater dorsiflexion at 3, 6, and 12 months post-rupture (p<0.001). Patients 
in this group also regained mobility (i.e. ability to comfortable weight bear) significantly 
more quickly than patients in the immobilization group (mean=6 versus 11 weeks, 
respectively; p<0.001). There was one re-rupture in each group. No differences between 
groups were found regarding plantar flexion range-of-motion or strength at any interval. 
These results suggest that early mobilization can lead to quicker recovery of dorsiflexion 
and quicker return to normal activities than immobilization in a plaster cast.   
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Costa et al (2006)129 conducted two RCTs comparing immediate weight bearing 
mobilization versus cast immobilization in patients with AT rupture. In the first RCT, 48 
patients consented to operative management of their injury (n=23 randomized to 
immediate mobilization group, n=25 to control group). In the second RCT, 48 patients 
consented to non-operative management of their injury (n=22 randomized to immediate 
mobilization group, n=26 randomized to control group). Patients in the operative trial 
began their respective rehabilitation assignments on the first post-operative day. Those in 
the immediate weight bearing mobilization group were placed in a carbon-fiber orthosis 
with three 1.5 cm heel-wedges, and those in the immobilization group were placed in a 
plaster cast. Patients were reviewed every two weeks for an eight week period, where the 
number of wedges or equinus position of the plaster was reduced at each visit. The cast or 
orthoses were discontinued at eight weeks. A significant difference was found in favor of 
the immediate mobilization group versus the control group for the time to return to 
walking (median=12.5 weeks versus 18 weeks, respectively; 95% CI=10 to 18 versus 18 
to 22; p=0.027) and stair climbing (median=13 weeks versus 22 weeks, respectively; 
95% CI= 10 to 18 weeks versus 18 to 22 weeks, respectively; p<0.023). There were no 
significant differences regarding time to return to work or sport, or quality-of-life 
assessments (EQoL and E5D). There were two re-ruptures in the treatment group due to 
breaching the rehabilitation protocol. The authors provided further evidence of improved 
functional outcomes for patients immediately mobilized following operative repair of AT 
rupture.  
In the second trial129 the same protocol was employed, with the exception of the orthosis 
or cast being removed at twelve weeks instead of eight and the removal of wedges or 
plaster at two-weekly intervals after the six week mark. There were no significant 
differences between any of the outcome measures in the second trial. There was one re-
rupture in the treatment group and one re-rupture in the control group. There were no 
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significant differences in any of the functional or clinical outcomes for the non-operative 
trial. The authors suggested, however, that the practical advantages associated with 
immediate mobilization do not appear to predispose patients to a higher re-rupture rate. 
They ultimately recommend immediate weight bearing mobilization for all AT rupture 
patients. It should be noted that, overall, these trials are subject to selection bias as older 
individuals were recommended non-operative treatment whereas younger and more 
active individuals were recommended operative treatment, ultimately preventing any 
between-group comparisons.  
More recently, Barfod et al (2014)103 completed a RCT comparing early motion and 
weight bearing (n=30) to early motion without early weight bearing (n=30) in the non-
operative treatment of patients with AT rupture. Both groups remained in a foot orthosis 
for eight weeks, with controlled early motion commencing at two weeks post-rupture. 
The only difference was that the intervention group could begin weight bearing 
immediately. The results yielded no significant differences between groups with respect 
to the Achilles Tendon Total Rupture Score (ATRS), heel-rise work, heel-rise height, 
time to return to work, or time to return to sport. A significant difference was found in 
favor of the early weight-bearing group for the quality of life during the eight weeks of 
treatment (p=0.009). There were three re-ruptures in the treatment group and two re-
ruptures in the control group. The authors concluded that immediate weight bearing 
appears to be a safe recommendation that can improve quality of life during the non-
operative treatment period of AT rupture patients.  
2.6 A Novel Non-Operative Option: Platelet-rich 
Plasma  
Platelet-rich plasma (PRP) is a generic term referring to products that contain autologous 
blood-derived platelets concentrated in a small volume of plasma. Specific PRP products 
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differ with respect to the commercial preparation system used, the absolute concentration 
of platelets, the presence or absence of platelet activators, the presence or absence of 
leukocytes, and the delivery technique to the tissue site7. PRP has been used in several 
fields of medicine including cardiovascular surgery, plastic surgery, dental surgery, and 
more recently in the treatment of orthopedic injuries130. Platelets are recognized as the 
primary source of the growth factors and proteins that are responsible for initiating and 
regulating tissue healing through the recruitment, proliferation, and differentiation of 
cells at the site of injury131. The theoretical concept that concentrating platelets at the site 
of tissue damage could optimize healing mechanisms provides the rationale for the 
continued research of PRP in the treatment of orthopedic injuries.   
2.6.1 Platelet Biology  
Platelets, also called “thrombocytes,” are cytoplasmic fragments of megakaryocytes and 
are formed in the bone marrow. They are round or slightly oval in shape, measuring 
approximately 2 µm in diameter. Platelets are anucleate but contain organelles and 
cellular structures such as mitochondria, microtubules, and granules (α, δ, λ)131. The α-
granules are most abundant132 and are the primary source of the growth factors and 
bioactive proteins that are involved in haemostasis and tissue healing133. 
Platelets circulating in the blood stream are inactive; they become activated by von 
Willebrand factor, collagen (exposed endothelium), or thrombin binding to respective 
platelet receptors which ultimately initiates a haemostatic intracellular signaling 
cascade134. Subsequently, histopromotive factors released by the platelets facilitate tissue 
healing via cellular chemotaxis, proliferation and differentiation of cells, removal of 
tissue debris, angiogenesis, and the formation of the extracellular matrix135,136. More 
detail regarding this process is provided below.  
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2.6.1.1 Proteins and Growth Factors in PRP and their Roles  
The α-granules of the platelet contain and secrete more than 60 bioactive proteins and 
growth factors that initiate and/or regulate tissue healing133.  Table 1133 outlines these 
proteins and growth factors in their functional categories and their respective biological 
role. It should be noted that, although proteins are grouped according to function, some 
may have multiple potential roles.  
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Table 1 Platelet α-granule contents and their functional categories. Secreted proteins with 
reported pro-angiogenic properties are underlined while those with anti-angiogenic 
potential are also identified (*). 
Reproduced with permission from Anitua et al. Autologous platelets as a source of proteins for healing and 
tissue regeneration. Thrombosis & Haemostasis 2004; 91. 4-15 
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2.6.1.2 Mechanism of Effect on Tissue  
Upon platelet activation, the α-granules fuse to the platelet cell membrane where the 
proteins and growth factors are completed to a bioactive state by the addition of histones 
and carbohydrate side chains. The secreted growth factors immediately bind to the 
external surface of cell membranes of cells of the damaged tissue via transmembrane 
receptors, ultimately initiating an intracellular signaling cascade which results in the 
expression of genes responsible for cellular proliferation, matrix formation, osteoid 
production, collagen synthesis, etc. After the initial burst of PRP-related growth factors, 
the platelets synthesize and secrete additional growth factors for the remaining seven 
days of their life span. Once the platelet is exhausted and dies off, the macrophage, which 
has arrived in the region via the vascular in-growth (i.e. angiogenesis) stimulated by the 
platelets, assumes the function of wound healing regulation by secreting some of the 
same growth factors as well as others137. 
2.6.2 Preparation of PRP 
A sample of PRP can be prepared in various pre-treatment settings, including a 
laboratory, operating room, or a clinic. Once a patient’s blood has been obtained, the 
autologous PRP sample can be prepared in minutes. There are three methods of 
preparation to obtain a sample of PRP: gravitational platelet sequestration (GPS), 
standard cell separators, and autologous selective filtration technology 
(plateletpheresis)131.  
The first method, the GPS is a table-top centrifuge system that separates anti-coagulated 
blood into three distinct layers of red blood cells, white blood cells, and plasma from 
bottom to top, respectively. The PRP yield is approximately 10% of the volume of blood 
drawn. It is important to note that not all centrifugal devices are adequate for the purposes 
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of preparing PRP, as the centrifugation force may be a critical step in yielding 
undamaged platelets in the PRP sample131. 
The second method, standard cell separators generally use a continuous-flow centrifuge 
bowl or a continuous-flow disk separation technique and both a hard (fast) and a soft 
(slow) spin, yielding platelet concentrations from 2 to 4 times baseline138. In this method, 
a full unit of blood is required from the patient. Most of the red blood cells and platelet-
poor plasma can be returned to the patient to maintain circulating volume139. 
The final method, selective filtration technology or plateletpheresis depends on a single-
use disposable proprietary filter designed to concentrate platelets from whole blood. The 
platelets are captured on the filter and are then harvested to provide a platelet-rich 
concentrate (PRC) without the need for centrifugation. This method yields a similar 
platelet concentration compared to the commercial centrifugation method140. 
2.6.2.1 Classification of PRP 
Each preparation method will yield a different PRP product with respect to platelet 
concentration, the presence (buffy-coat) or absence of leukocytes, and the need of a 
platelet activator (Table 2)7. It is also important to note that an individuals’ platelet count 
can vary considerably on different days, which could also impact the concentration of 
platelets in a sample of PRP141. Furthermore, this information is rarely documented in 
PRP trials, which ultimately limits the ability to make comparisons and meta-analyze 
data across these trials. DeLong et al (2012)7 have proposed a classification system that 
enables efficient identification of the contents in a PRP sample (Figure 8). Identifying 
and classifying the contents of PRP samples is a major step towards potentially 
discovering an optimum dosage or preparation method of PRP7. 
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Table 2 Plasma-Based and Buffy Coat-Based PRP Systems 
Reprinted from The Journal of Arthroscopy & Related Surgery, 28 (7), Delong, Russel, & Mazzocca, 
Platelet rich plasma: the PAW classification system, 998-1009, 2012, with permission from Elsevier  
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Figure 8 PRP "PAW" Classification System 
Reprinted from The Journal of Arthroscopy & Related Surgery, 28 (7), Delong, Russel, & Mazzocca, 
Platelet rich plasma: the PAW classification system, 998-1009, 2012, with permission from Elsevier  
2.6.3 Delivery of PRP 
Once a PRP sample is prepared, it is stable in the anticoagulated state for eight hours142. 
In some instances anticoagulants are used to maintain platelet viability. Anticoagulant 
citrate dextrose-A (ACD-A) and citrate phosphate dextrose (CPD) are the most 
commonly used, with the latter being less effective of the two143. Upon delivery or 
application of PRP, the platelets must be activated to release the contents of their α-
granules, which can be accomplished exogenously or endogenously. Exogenous 
activation via external clotting factors results in rapid coagulation of platelets and clot 
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formation and for this reason are generally applied manually to the tissues, rather than 
administered by injection7. Common exogenous platelet activators include thrombin, 
calcium chloride, and calcium chloride plus thrombin. Endogenous activation occurs via 
the platelets binding to exposed tissue collagen and, to a lesser extent, needle-induced 
bleeding from an injection144.  
2.6.4 PRP in the Treatment of Orthopedic Injuries  
A meta-analysis was conducted by Sheth et al (2012)130 to determine the efficacy of 
autologous blood concentrates in the treatment of orthopaedic bone and soft-tissue 
injuries. They screened 895 potential studies in Medline and Embase databases and 
identified 23 randomized controlled trials and ten prospective cohort studies that 
compared PRP or autologous blood concentrates with a control therapy in patients with 
an orthopaedic injury. Of the 33 studies, 10 examined ligamentous injuries, 14 examined 
bone injuries, and 9 examined tendinous injuries.  A total of 27 different functional 
outcome measures were used, 11 of which served as the primary outcome of the study. 
Of the 23 RCTs, six showed that PRP provided a significant functional benefit, 15 
demonstrated no difference, one showed that the control provided significant functional 
benefit, and one did not evaluate functional outcomes. Of the 10 prospective studies, 3 
showed PRP provided a significant functional benefit, 6 demonstrated no difference, and 
1 showed that the control provided significant functional benefit. There were no 
commonalities amongst the studies that found a benefit to PRP with respect to: the type 
of procedure or pathology; the PRP manufacturer/preparation method; the use of an 
anticoagulant; the activation method; the number of PRP treatment applications; or the 
volume of PRP used per treatment. The authors concluded that their analysis was limited 
by marked variability among the studies.. Ultimately, these results suggested that there 
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was uncertainty regarding the evidence supporting the use of PRP in the treatment of 
orthopaedic injuries.  
A similar conclusion was reached by Willits et al (2013)6 who reviewed the literature 
regarding the use of PRP in the treatment of orthopaedic injuries. Many of the studies 
included in the aforementioned meta-analysis130 were part of this review. Studies were 
selected for review based on the highest levels of evidence. A total of 17 studies were 
selected for review: 13 RCTs, two retrospective cohort studies, one prospective cohort 
study, and one pilot study. Of the 17 studies, 10 examined PRP in the tendon healing, 2 
examined PRP in bone healing, 2 examined PRP in muscle healing, and 3 examined PRP 
in the treatment of intra-articular pathologies. A systematic review and subsequent meta-
analysis on the clinical efficacy of PRP in arthroscopic rotator cuff repair was also 
reviewed. The conclusions of this review suggest no clear indications for the use of PRP 
in the treatment of musculoskeletal injuries. This is largely due to a lack of homogenous, 
high level studies, which precludes attempts to compare results across PRP studies.  
2.6.5 PRP in the Treatment of Achilles Tendon Ruptures: A 
Review of the Literature  
2.6.5.1 Animal Trials  
In an animal study, Aspenberg & Virchenko (2004)9 examined effect of platelet 
concentrate (PC) injections on AT repair in an established rat model. Sprague-Dawley 
rats (n=263) had their AT surgically transected transversely 3 mm proximal to the 
calcaneal insertion and a 3 mm long segment was also removed to enlarge the defect. The 
rats were then randomized to the treatment or control (saline) group by taking coloured 
marbles out of a hat, randomizing groups of ten rats at a time. Whole blood was collected 
from three donor rats to prepare the PC sample for injection. The injections took place six 
hours after the transection. Initially, 20 rats were randomized to receive the PC injection 
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or control injection. At eight days, the rats were killed and their AT was removed to 
undergo mechanical evaluation using a material-testing machine that fixed each end of 
the tendon between two metal clamps and pulled at a speed of 1mm/s until failure. Peak 
force, stiffness, and energy uptake was recorded for each mechanical evaluation. After a 
significant improvement was found for this initial test, a repeat experiment was 
performed which did not reach statistical significance. The authors then conducted three 
additional experiments using the same parameters. Four more experiments were 
conducted with different times allotted for healing (11, 14, 21, and 28 days). Mechanical 
evaluation of the tendons occurred for each of these additional experiments, and 
histological evaluation of the tendons occurred in the 11 day- and 21 day healing 
experiments. The eight-day results indicated a significant increase in force at failure 
(mean=27%; 95% CI=10-44%; p=0.001) and stiffness (mean=35%; 95% CI=14-56%; 
p<0.001) in favor of the PC group. No significant differences were observed regarding 
maximum stress or energy uptake between groups. The reported mechanical results for 
the remaining healing times are as follows: the force at failure was increased at for all 
times (p<0.001) with the largest difference occurring at 21 days (mean=36%; 95% CI=5-
67%); the transverse area was increased by PC treatment at 8 and 11 days, but after 14 
days the areas were similar in both groups; the maximum stress was increased in all PC 
treatment groups (p=0.004); The stiffness in all groups increased with healing time 
(p<0.001) and with PC (p<0.001), with the largest effect of PC at 11 days (mean=41%; 
95% CI=12-70%); the energy uptake in all groups was increased with time (p<0.001) and 
with PC treatment (p=0.02), with the largest effect at 21 days (mean=18%; 95% CI=-
12%-48%). The histological findings indicated that PC treatment had no detectable effect 
at 11 days (p=0.40), but at 21 days the tendon calluses in the PC group were more mature 
(p=0.02). Although promising, the results of this study should be interpreted cautiously as 
the methodology of the study should be questioned. The authors did not clearly state a 
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priori that it was their intention to conduct five sets of identical trials, as it seems that 
they conducted the additional trials due to the second trial not reaching statistical 
significance. Furthermore, the effect of PC in these trials was highly variable which the 
authors attribute to premature platelet activation in some batches of PC samples. The 
authors ultimately concluded that a single PC injection can improve tendon repair in rats 
and that these effects can be seen up to four weeks post-injection.  
Stemming from the results of Aspenberg & Virchenko (2004)9, Virchenko & Aspenberg 
(2006)10 evaluated the interplay between platelet-concentrate (PC) injections and 
mechanical loading in a rat model in an attempt to explain the lasting effects of a single 
PC injection on AT repair. Tendons were either unloaded with Botulinum toxin A (Botox) 
or mechanically stimulated in activity cages. Sprague Dawley rats (n=130) were used in a 
series of separate trials with ten rats in each respective group. All experiments included 
tendon transection with spontaneous healing and were evaluated mechanically. All 
experiments were evaluated after 14 days except the final experiment which was 
evaluated at 5 days. In the first experiment, 20 rats received Botox injections and 
underwent tendon transection seven days later, at which time paralysis (i.e. unloading) 
appeared complete. Six hours after tendon transection, the rats were randomized to 
receive an injection of PC (n=10) or a buffer control injection (n=10). This trial 
demonstrated that with unloading by Botox, there were no stimulatory effects of PC 
which suggests that mechanical loading is a prerequisite for stimulation of repair by 
platelets. In the next experiment, 20 rats were randomized to activity cages or normal (i.e.  
non-activity) cages. After an acclimatization period to their cage, the rats underwent 
tendon transection and returned to their cages. Upon mechanical evaluation 14 days later, 
the tendons from activity cages had increased force, energy uptake, and transverse area. 
This experiment was then repeated with the addition of platelet gel, yielding 4 separate 
groups: activity cage rates with platelet gel; activity cage rats with no platelet gel; normal 
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cage rats with platelet gel; and normal cage rats with no platelet gel. These results 
showed that platelets increased stiffness, reduced area, and increased stress at mechanical 
failure of the tendon. There was no evidence to suggest that cage activity influenced the 
tendon’s response to platelets. The authors then combined the results of the activity cage 
experiments (excluding platelet-treated groups from the aforementioned trial) and found 
that activity increased force (mean increase=12%; 95% CI=0.8-23%; p=0.04), energy 
uptake (mean increase=18%; 95% CI=2-34%; p=0.04), and tendon area (mean 
increase=24%; 95% CI=4.6-43%; p=0.02). In the final experiment, 40 rats received 
Botox injections, followed by randomized to platelet or control treatment after tendon 
transection and were evaluated after five days. These results showed that platelet 
treatment increased force (mean increase=37%; 95% CI=11-63%; p=0.01), stiffness 
(mean increase=52%; 95% CI=15-87%; p=0.01), and area (mean increase=64%; 95% 
CI=-25-154%; p=0.009). In summary, these results suggest that activity (i.e. mechanical 
loading) increases size (and thereby force and energy) of the tendon and platelets 
improve material properties early in the healing process. This appears to occur in 
sequence, rather than in synergism, as the effects of platelets are absent after 14 days 
without mechanical loading. This proposed principle, however, does not show directly 
what time point mechanical loading starts to stimulate repair. With respect to clinical 
implications in humans, the authors suggest that these results support the use of 
mobilization in AT rupture rehabilitation and that platelet injections can increase the 
response of tendon cells to loading of the tendon.  
Lyras et al (2009)145 examined the influence of PRP on angiogenesis during the early (i.e. 
inflammatory and proliferative) phase of healing in 48 rabbits. The rabbits were 
randomized to receive PRP (n=24) or a saline injection (n=24) during surgery in both of 
their transected ATs. Six rabbits from each group were sacrificed at one, two, three, and 
four weeks, respectively, at which time an immunohistochemical analysis was performed 
46 
 
 
 
 
 
on the tendons. Microscopic images of the tendons were obtained and an angiogenesis 
analysis was performed using an established technique. Vessel density (mean number of 
vessels per mm2) was significantly higher in the PRP group (mean=495) than the control 
group (mean=322) at one week (p<0.0001) and at two weeks (mean=1736 versus 309; 
p<0.0001). At three and four weeks, the control group had significantly higher vessel 
density than the PRP group (p<0.0001). These results suggest that PRP can significantly 
increase the vascularity of injured ATs in the early stages of healing, corresponding to the 
inflammatory and proliferative phases. Given that tendons are poorly vascularized 
structures, an increase in vascularity could contribute to more substantial healing and 
remodeling of the tendon. It is important to note that although these results demonstrate 
increased vascularity, there was no biomechanical or functional evaluation of these 
tendons. These results, therefore, do not have any functional implications.   
In 2010, Lyras et al146 investigated the effect of PRP on transforming growth factor β1 
(TGF-β1) expression during tendon healing in rabbits. The authors hypothesized that 
PRP alters the tendon healing process by altering the expression of the multifunctional 
growth factor TGF-β1. Expression of TGF-β1 was assessed by immunostaining the 
specimens with anti-TGF-β1 primary antibody to which TGF-β1 would bind to. A total 
of 48 rabbits (96 limbs) were randomized to receive a PRP injection or no injection upon 
surgical transection of their AT. TGF-β1 levels were assessed at one, two, three, and four 
weeks post-transection. The results indicated that the PRP group had significantly higher 
expression of TGF-β1 at one and two weeks (p<0.0001), and the control group had 
significantly higher TGF-β1 expression at three and four weeks (p<0.0001). In the 
control group in this study, TGF-β1 expression progressively increased over the four 
week period. Conversely, TGF-β1 expression progressively decreased in the PRP group. 
Ultimately, these results suggest that PRP alters the temporal expression of TGF-β1. The 
significance of this is not completely understood, but the authors suggest that further 
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study of how various growth factor expression is altered after PRP injections could lead 
to a more thorough understanding of how PRP affects the healing process.  
Kaux et al (2012) studied the effects of PRP on the healing of surgically transected ATs 
of 120 Sprague-Dawley rats. The rats received either a PRP injection (n=60) or a control 
injection (n=60), defined as a “physiological solution”. It was not explicitly stated how 
the rats were allocated into treatment or control groups. Injections were performed two 
hours after the tendons had been surgically transected. Biomechanical and histological 
analyses were performed at 5, 15, and 30 days post-injection. Biomechanical evaluation 
was performed using a traction-compression testing machine, and values for ultimate 
tensile strength (UTS) were normalized by accounting for the cross-sectional area of the 
tissue. The UTS represents the amount of force applied to the tissue at its failure point. 
Histological evaluation was accomplished by staining sections of the tendons and 
subsequently obtaining photomicroscopic images which enabled the quantification of 
collagen content. Additionally, tenocyte proliferation was assessed by quantitiative 
reverse-transcription polymerase chain reaction (RT-PCR). The biomechanical results 
showed that the UTS was higher in the PRP group than the control group at all time 
points, with statistically significant differences at 15 and 30 days (p<0.05). There were no 
obvious histological differences in tissue organization between groups. There was, 
however, increased deposition of structured collagen fibres at day five in the PRP group 
(p=0.03). Ultimately, these results suggest that PRP influences the early phase of tendon 
healing from a histochemical standpoint, which results in stronger mechanical resistance 
during later phases of healing.  
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2.6.5.2 Human Trials  
2.6.5.2.1 Operative Trials  
Sanchez et al (2007) examined the effect of PRP injection and a platelet-rich fibrin matrix 
(PRFM) scaffold application in 12 athletes who underwent open surgical repair of their 
AT rupture. Six athletes received the PRP treatment and their outcomes were 
retrospectively compared with six athletes who underwent open surgical repair with no 
PRP augmentation. Identical surgical procedures were performed in each group, with the 
addition of a PRP injection into tendon fibers after the tendon was sutured followed by a 
PRFM application. The PRP treatment group experienced significantly earlier restoration 
of functional range of motion (7 versus 11 weeks; p<0.05), earlier time to running (11 
versus 17 weeks; p<0.05), and earlier time to return to normal training activities (14 
versus 21 weeks; p<0.05). Additionally, the mean increase in cross-sectional area of the 
operated tendon was significantly less in the PRP group than the control group (298% ± 
90% versus 499% ± 91%, respectively; p=0.009). There were no re-ruptures in either 
group. The authors concluded that the addition of PRP and PRFM scaffolding in open 
suture repair of AT ruptures could provide opportunities for enhanced healing and 
functional recovery, although a larger RCT is warranted to confirm these results 
In a randomized, patient-blinded study, Schepull et al (2011)147 consecutively recruited 
30 patients for PRP injection (n=16) or no injection (n=14) at the time of open surgical 
repair of an AT rupture. All patients were operated on within five days of their injury. 
The primary outcomes were the E-modulus (which describes the elastic property of a 
tissue) at 7 weeks and the heel raise index at 52 weeks. There were no significant 
differences in the E-modulus between groups at any time point. Furthermore, there was 
no significant differences were found in the heel raise index at 52 weeks. The patient-
reported Achilles tendon rupture score (ATRS) was significantly lower (i.e. inferior 
49 
 
 
 
 
 
function) in the PRP group than the control group (78 versus 89; p=0.014) at 52 weeks. 
There was one re-rupture in the PRP group who was lost to follow-up, and no reruptures 
in the control group. The authors concluded that there was no clinical or functional 
benefit to PRP treatment in AT surgical repair. One possible explanation for the lack of a 
treatment effect is the fact that patients were immobilized in a plaster cast for seven 
weeks post-surgery, as it has been demonstrated in animal studies that there is an 
interplay between autologous platelet augmentation and early mechanical loading in AT 
repair10. A weakness of this study is that there was no control injection, which prevented 
blinding of the clinical investigators to the treatment group of the patients. Investigator 
blinding could have been accomplished by having saline injections for the control group, 
and masking the contents of all syringes with opaque tape. 
De Carli et al (2015)148 alternately assigned 30 patients on a case-by-case basis to receive 
PRP (n=15) or no PRP (n=15) during surgical repair of AT rupture. Liquid PRP and PRP 
gel was applied at the suture site in the treatment group. All surgeries were performed 
within three days of the rupture. Patient-reported outcome measures were assessed at 1, 3, 
6, and 24 months and included the VISA-A, FAOS, and VAS. Functional outcome 
measures were assessed at 6 months and included isokinetic strength assessment and 
jumping capability assessment. MRI and ultrasound images were also obtained at six 
months. The results of this study demonstrated that there was no statistically significant 
differences in any of the patient-reported or functional outcome measures. Furthermore, 
ultrasound and MRI revealed similar morphostructural findings in both groups with 
respect to tendon integrity and structure. The authors concluded that, due to substantial 
equivalence in structural and functional results between groups, there appears to be no 
clinical benefit to the addition of PRP to surgical treatment of AT rupture. A weakness of 
this study is the alternate assignment of patients to treatment or control groups, which 
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enables investigators to deduce the allocation to grouping. Additionally, there was no 
mention of whether or not patients were blinded to group allocation.  
2.6.5.2.2 Non Operative Trials  
In a retrospective comparative study, Kaniki et al (2014)8 compared the clinical and 
functional outcomes of consecutively recruited patients (n=73) who received PRP 
injections in the non-operative management of AT rupture to a historical control group 
who solely underwent non-operative management (n=72). All injections were performed 
within 14 days of rupture. The primary outcome was isokinetic strength ratio for plantar 
flexion of the injured ankle to the uninjured ankle at one year and two years. Secondary 
outcomes included ROM, calf circumference, Leppilahti score, and AOFAS score. The 
mean isokinetic strength ratio at 30°/s for the PRP and non-PRP groups was 87.9% 
(±19.6%) and 92.2% (±33.9%), respectively, at one year and 87.8% (±15.7%) and 91% 
(±35.7%), respectively, at two years. At 60°/s, the isokinetic strength ratio between the 
PRP and non-PRP groups was 90% (±23.3%) and 87.6% (±25.6%), respectively at one 
year and 89.6% (±21.3%) and 84.8% (±21.1%), respectively, at two years. The mean 
between-group differences were not statistically significant for any speed at any time 
point. Furthermore, there were no statistically significant differences between groups for 
any of the secondary outcomes. Two patients in the PRP group and three patients in the 
control group experienced re-ruptures. Ultimately, these results suggest that there is no 
measureable clinical or functional benefit from PRP in AT healing. A limitation of this 
study is the timing of the PRP injections. Patients were injected up to 14 days post-
rupture, corresponding to the late proliferative (i.e. secondary) phase of tendon healing. 
In the present study, we aimed to address this limitation by injecting patients in the late 
inflammatory (i.e. primary) or early proliferative healing phase in hopes that the effects 
of the PRP would be more pronounced in this phase. 
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2.7 Summary  
The AT is the most commonly ruptured tendon in the human body; occurring more often 
in men and in individuals between 30 and 39 years of age.  There is some evidence that 
the incidence of AT rupture increases within the last two to three decades. AT ruptures 
are more likely to occur during sporting activities, especially those that involve rapid, 
eccentric, impact loading. Additionally, there are several documented risk factors that can 
potentially predispose an individual to tendon rupture, but consensus is lacking amongst 
researchers regarding the definitive contributions of these factors.  
AT ruptures can be treated operatively or non-operatively, although the optimal treatment 
remains controversial. Traditionally, operative treatment of AT rupture has been 
associated with a lower re-rupture rate compared to non-operative treatment but also a 
higher complication rate.  However, there is evidence to suggest that the rehabilitation 
protocol, not the initial treatment, has a significant influence on re-rupture rate. 
Specifically, when an accelerated functional rehabilitation protocol is followed, re-
rupture rates are similar between patients treated operatively and non-operatively.  
The effectiveness of PRP in the treatment of musculoskeletal injuries remains 
controversial because studies evaluating its effectiveness use different preparation 
methods, ultimately yielding a different PRP product with respect to the platelet 
concentration, the presence or absence of leukocytes, and the need for a platelet activator. 
Furthermore, this information is rarely documented, limiting the ability to make accurate 
comparisons across studies.  
Achilles tendon healing is a slow process that occurs in three overlapping phases: the 
inflammatory phase; the proliferative phase; and the remodeling phase. The inflammatory 
phase lasts approximately 24 to 48 hours and is characterized by the activation of 
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platelets and neutrophils which leads to the release of bioactive factors that initiate the 
healing response. Approximately three to five days after injury, the proliferative phase 
begins whereby angiogenesis and collagen production increases. At approximately six 
weeks, the remodeling phase begins which results in a gradual increase in type I collagen 
synthesis. This phase can last for several years. Since platelets activation is generally the 
most pronounced in the inflammatory phase, it is thought that PRP could have a more 
pronounced effect if introduced to the ruptured tendon as early as possible, which 
provides the rationale for the timing of the injections in this study.  
The use of imaging (US and MRI) as a measure of outcome in tendon healing has been 
attempted by researchers, although the criteria used to assess tendon healing differs from 
trial to trial and the relative importance of each criteria to tendon healing has not been 
established. Both US and MRI are well-suited to tendon evaluation, with MRI having the 
advantages of a broader anatomic overview and excellent soft-tissue contrast and US 
having the advantages of being more rapidly performed, more cost-effective, and the 
ability to perform dynamic evaluations. Ultimately, it has been demonstrated that US and 
MRI are grossly comparable with respect to sensitivity and specificity in the diagnosis of 
tendon pathologies. To our knowledge, however, no studies have longitudinally evaluated 
and attempted to quantify the healing AT using both US and MRI.  
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Chapter 3  
3 Objectives  
 
3.1 Primary Objective  
Our primary objective was to compare the radiological assessments of tendon integrity 
and healing using ultrasound and magnetic resonance imaging between patients who 
received two ACP® injections and patients who received two placebo injections in the 
non-operative treatment of Achilles tendon ruptures. 
3.2 Secondary Objectives  
The secondary objective of this study was to compare the isokinetic strength scores, 
Ankle-Hindfoot Scale (AOFAS) scores, Leppilahti scores, Achilles Tendon Total 
Rupture (ATRS) scores, range of motion, and calf circumference between patients who 
received two ACP® injections and patients who received two placebo injections in the 
non-operative treatment of Achilles tendon ruptures. 
3.3 Overall Study Objective 
The ultimate objective of this study was to determine whether the results support 
conducting a larger RCT. This thesis is based on the six-month outcomes for 20 patients. 
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Chapter 4  
4 Methods  
4.1 Study Design  
This study was a single-centre randomized trial where the patients and outcome assessors 
were blind to group allocation. Patients (n=20) were consecutively recruited from the 
Fowler Kennedy Sports Medicine Clinic upon referral from emergency rooms in London, 
Ontario, Canada and surrounding areas. This study was approved by the institutional 
Health Sciences Research Ethics Board at Western University (Appendix A).  
4.2 Eligibility Criteria  
Eligible patients had a complete rupture of the Achilles tendon that was confirmed by 
diagnostic ultrasound within seven days of the initial injury, were able to speak and 
understand the English language, were willing to follow the recommended rehabilitation 
protocol, and were between the ages of 16 and 70 years.  Patients were excluded if they 
had previous injury to the Achilles tendon, significant ipsilateral injury (e.g. bone 
fracture), open injury to the Achilles tendon, avulsion of the Achilles tendon from the 
calcaneus, or fluoroquinolone-associated rupture. We excluded patients who were 
pregnant, had any neurological or collagen or vascular disease (stroke, Ehlers-Danlos 
syndrome, cerebral palsy), diabetic, or unable to tolerate magnetic resonance imaging 
(MRI).  
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4.3 Treatment & Rehabilitation Protocol  
4.3.1 Acute Treatment  
All patients were prescribed a removable below-knee orthosis with a 2 cm heel-lift upon 
diagnosis of an Achilles tendon rupture. The heel-lift provided approximately 20 degrees 
of plantar-flexion at the ankle joint, corresponding to the optimal position for healing of 
the Achilles tendon fibres. Patients were instructed to remain non-weight-bearing in the 
Aircast™ brace until six weeks post-injury during all activities of daily living with the 
exception of bathing. 
4.3.2 Intervention Protocol  
Patients were randomized by computer to receive either Autologous Conditioned Plasma 
(ACP®) or placebo (saline). All patients, including those in the placebo group, followed 
an identical injection procedure with the exception of the contents of the injection.  
Additionally, all patients had an extra vial of blood drawn (approximately 10 cc’s) to 
obtain a complete blood count (CBC) analysis at the time of injection. The clinician 
(KW), data collectors, and patients were blinded to group allocation. Blinding was 
accomplished by having a third-party (nurse) perform the computer randomization and 
prepare the injections. The injections were prepared in a private room where the contents 
of the syringe were masked by opaque tape.  
4.3.3 Autologous Conditioned Plasma (ACP®) 
Approximately 10 cc’s of blood was drawn from each patient into an Arthrex ACP® 
double-barrel syringe and spun in a table-top Rotafix 32A centrifuge (Figure 9) at 1500 
rpm for five minutes. This process yielded a distinct three-layer distribution of blood 
components (Figure 10). The double barrel syringe enables the extraction of only the top 
plasma layer (platelet-rich) without significant contamination from the other two layers. 
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The amount of plasma obtained from this method ranged from 3 to 4 cc’s. Approximately 
0.25 cc’s of ACP® was transferred to a separate vial in order to undergo a platelet and 
leukocyte quantification analysis.  
Once the plasma had been isolated in the syringe and prepared for injection, the clinician 
(KW) used palpation and ultrasound measurements to identify the location of the rupture 
for injection. The injection site was sterilized and then anaesthetized with lidocaine (2%).  
The ACP® was subsequently injected into the marked site. A second injection was 
administered two weeks later following an identical protocol. 
                                   
Figure 9 Centrifuge 
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Figure 10 Three-layer ACP  
4.3.4 Rehabilitation  
Patients were advised to begin physiotherapy at four weeks post-injury, placing an 
emphasis on active plantar/dorsi flexion to neutral, inversion/eversion below neutral, 
modalities to control swelling, knee/hip exercises, non-weight-bearing cardiovascular 
work, and hydrotherapy. From six to eight weeks, patients were advised to remove the 
heel-lift from their Aircast™ boot and begin weight-bearing as-tolerated. Stretching and 
resistance exercises, proprioceptive training, and cardiovascular training with weight-
bearing as-tolerated were also introduced in the protocol. During weeks eight through 
twelve, patients were weaned off of the Aircast™ boot while using crutches as necessary, 
then weaned off of the crutches. Progressive increases in strength, proprioception, and 
range-of-motion (ROM) were also emphasized. After 12 weeks, patients were advised to 
continue progressing with strength exercise, proprioception, and range-of-motion, while 
also introducing plyometric training and sport-specific retraining if applicable.  
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4.4 Primary Outcome – Healing  
Healing was assessed through a series of ultrasounds and MRI’s. A single, blinded 
radiologist (AS) interpreted all images and an ordinal estimation of the healing 
percentage (i.e. 0 to 25%; 26 to 50%; 51 to 75%; 76 to 100%) of the tendon was provided 
based on objective criteria within each image. These criteria, as well as the methods for 
obtaining the images are listed below.  
4.4.1 Ultrasound  
Ultrasound images were obtained by an experienced musculoskeletal sonographer using a 
Phillips IU22 machine with the linear L12-5 probe (Phillips, Amsterdam, Netherlands). 
Patients laid prone with their feet hanging over the edge of the exam table in slight 
dorsiflexion. Transmission gel was used to optimize image quality. Sagittal images were 
obtained by aligning the long axis of the ultrasound probe with the long axis of the 
Achilles tendon beginning at the tendon insertion, moving proximally to the 
musculotendinous junction while simultaneously sweeping across the width of the tendon 
mediolaterally to visualize the tendon’s full extent. Transverse evaluation was 
accomplished by orienting the long axis of the transducer 90° to the long axis of the 
Achilles tendon and sliding the probe from distal to proximal. Dynamic imaging 
consisting of dorsi- and plantarflexion maneuvers while positioning the probe in the 
sagittal plane was carried out in all patients at baseline and after 6 weeks. Colour Doppler 
was applied in the sagittal and transverse planes in the vicinity of the tear to assess for 
hyperemia.  
Representative still images and cine clips on ultrasound were captured for review by a 
musculoskeletal radiologist (AS) with over 20 years of experience. Specifically, the 
radiologist (AS) quantified the length of the gap (average), presence of hyperemia on 
59 
 
 
 
 
 
colour Doppler, antero-posterior diameter of the gastrocnemius (injured and contralateral 
side), echogenicity of the gastrocnemius (isoechoic, hypoechoic, hyperechoic), location 
of the tear (distance from the calcaneal tuberosity), background tendon quality (normal or 
tendinosis), maximum tendon diameter remote from tear, and the presence of 
calcification. At six weeks and onward, dynamic uniform motion of the tendon was also 
evaluated. The main criteria factoring into the healing estimation for US are: the size or 
presence of a gap; the degree of uniform motion on dynamic evaluation; and the 
echogenicity and continuity of the tendon fibres.  
4.4.2 MRI  
MR images were obtained using a 1.5 T MRI scanner (CVMR, General Electric, 
Milwaukee, USA) with phased array extremity coil. Patients laid supine on the MRI table 
and then entered the MR tunnel.  Images were obtained in the sagittal and axial planes 
(see Appendix D for detailed description of imaging sequences). Similar to the ultrasound 
protocol, these images were evaluated against objective criteria to ultimately yield a 
percent-healing estimation. Specifically, the radiologist (AS) quantified the length of the 
gap (average), signal intensity at the site of the tear relative to normal tendon signal (T1, 
T2, inversion recovery), presence of altered tendon contour, shape of the tendon (circular 
or ellipsoid), anterior margin of the tendon (concave or convex), maximum diameter of 
tendon at tear site, presence of peritendinous edema (none, mild, moderate, severe), 
gastrocnemius signal intensity (normal, mild fatty-infiltration, moderate fatty-infiltration, 
marked fatty-infiltration), location of tear from calcaneal tuberosity, background tendon 
quality (normal or tendinosis), and maximum tendon diameter remote from tear. The 
main criteria factoring into the healing estimation for MRI are: the size or presence of a 
gap; the T2 signal at the tear site; and the overall appearance and continuity of the 
tendon.  
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4.5 Secondary Outcomes  
4.5.1 Isokinetic Strength  
Strength was assessed using a Biodex Multi-Joint System 3 Dynamometer (Biodex 
Medical, Shirley, NY) (Figure 11) at six months and one year post-injury. The patient 
was seated with their hip flexed at 45° supported by a thigh rest with the thigh strapped 
into place to prevent upper-leg involvement in the strength assessment. The knee was 
flexed at approximately 30° so that the tibia and fibula were parallel to the floor. The 
medial malleolus was aligned with the dynamometers axis-of-rotation and the foot was 
fixed to the dynamometer footplate by two Velcro straps and a modified ankle strap.  
Patients performed a set of reciprocal plantar and dorsiflexion contractions at three 
different testing velocities (30°/s, 60°/s, and 240°/s) on both the injured and uninjured 
ankle. A brief familiarization period was allotted prior to each new set of contractions.   
There were four reciprocal contractions at 30°/s and 60°/s and ten at 240°/s. One minute 
of rest was given between each test velocity. Peak torque (Nm) for plantar flexion and 
dorsiflexion was calculated by averaging peak torques of individual contractions at each 
velocity.  
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Figure 11 Biodex Dynamometer 
4.5.2 Range of Motion  
Plantar flexion and dorsiflexion was measured by a graduate student using a standard 
goniometer. The graduate student was trained prior to participant testing by a certified 
athletic therapist. The patient sat at the edge of the examination table with their knees and 
ankles positioned in a neutral position at approximately 90°.  The axis of rotation was 
immediately inferior to the lateral malleolus and the long axis of the fibula was used as 
the fixed lever arm. The moving lever arm was aligned with the fifth metatarsal. The 
patient was instructed to move into plantar and dorsiflexion and the lever arm was moved 
accordingly to record the amount of movement in degrees relative to the neutral position. 
Assessment of plantar- and dorsiflexion ROM has high intra-rater reliability using a 
goniometer, however, there is little evidence to support high inter-rater reliability due to 
differences in rater training, the positioning of the patients, and the landmarks used149.  
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4.5.3 Calf Circumference  
Calf circumference was measured in centimeters using a standard flexible tape measure. 
Patients were seated at the edge of the examination table with their lower legs relaxed off 
of the table. Measurements were taken approximately halfway between the patella and 
the ankle joint at the largest muscle bulk in the gastrocnemius.  
4.5.4 Leppilahti Score 
The Leppilahti is a disease-specific and functional outcome measure that evaluates 
patient ratings of pain, calf muscle weakness and stiffness, footwear restrictions, range of 
motion, and progress satisfaction. Isokinetic strength data for patient plantar and 
dorsiflexion (30°/s, 60°/s, and 240°/s) is incorporated in the traditional scoring of the 
Leppilahti. This outcome measure was able to detect change in a similar sample of 
patients in a previous trial at our center comparing operative to non-operative 
management of AT rupture.  
4.5.5 Ankle-Hindfoot Scale (AOFAS) 
The AOFAS is an objective functional scale and a region-specific quality of life measure. 
This questionnaire examined the patient’s function (seven items), alignment (one item) 
and pain (one item) with a combination of subjective grading from the patient and 
objective evaluation from the physician. Pain was rated by the patient and alignment was 
objectively rated by the physician; functional questions were answered by both the 
patient (four items) and the physician (three items). The AOFAS has demonstrated 
concurrent validity150,151, criterion validity151, construct validity152, and test retest 
reliability151 in patients with various foot and ankle disorders. 
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4.5.6 Achilles Tendon Total Rupture Score (ATRS) 
The ATRS is a self-administered instrument for measuring patient outcomes after 
treatment for Achilles tendon rupture. There are ten items in the questionnaire that 
assesses the patient’s limitations as a result of their symptomology (i.e. pain, stiffness, 
etc.) and limitations in various physical activities (i.e. walking, running, climbing stairs, 
etc.). For each item the patient was required to rate their limitations on a scale of 0 
(severe limitations) to 10 (no limitations).  The sum of all responses represented their 
overall score out of 100. This outcome measure was originally in the Swedish 
population153, however, it has demonstrated adequate validity, reliability, responsiveness, 
and sensitivity in English-speaking populations as well154. 
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4.6 Timeline for Outcome Measures  
Outcome 
Measure 
0 W 2 W 4 W 6 W 8 W 12 W 24 W 1 Y 
US X X X X X X X  
MRI    X  X X  
AOFAS X   X  X X X 
ATRS X   X  X X X 
ROM    X  X X X 
Leppilahti       X X 
Strength       X X 
Abbreviations. W = weeks; Y = year; US = ultrasound; MRI = magnetic resonance 
imaging; AOFAS = American Orthopedic Foot & Ankle Society; ATRS = Achilles 
tendon rupture score; ROM = range of motion   
Table 3 Timeline for all study outcome measures 
4.7 Plan for Analysis  
We used SPSS version 22 to perform all data analyses except weighted-kappa 
calculations, for which we used MedCalc version 15.8. The demographic characteristics 
of each group were presented using descriptive statistics; means and standard deviations 
were used for continuous variables (e.g. age, height, weight) and proportions for nominal 
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variables (e.g. gender, affected foot, activity at onset). Because our sample is small, we 
used non-parametric analyses to test for between-group differences for all outcome 
measures. For the ordinal estimations of percent healing using US and MRI, we used the 
Mann-Whitney U test to determine the mean rankings of healing for each group. 
Additionally, a weighted-Kappa was used to measure the agreement between US and 
MRI assessments at coinciding time points. For outcome measures with baseline 
measurements (ATRS, AOFAS) we used the Mann-Whitney U test to determine the 
median difference in the change scores between baseline and each time point for each 
group.  We used the Mann-Whitney U test when baseline data was not available to 
determine the median difference in outcome measures at each time point. In all instances, 
the independent variable was the treatment group and the dependent variable was the 
ordinal or continuous outcome measure. Outcome data for continuous variables for each 
group are presented as the median difference with the 25th to 75th interquartile range. A 
p<0.05 was considered statistically significant. The intention-to-treat (ITT) principle was 
followed for one patient who was randomized to the ACP® group but was given saline 
injections due to technical difficulties with the centrifuge. We used last outcome carried 
forward to fill any missing end point data. Specifically, one patient in the saline group 
was missing his one-year range-of-motion, calf circumference, and isokinetic strength 
assessments because he moved out of the province; these outcomes carried forward form 
the six month assessment. He was able to complete all one-year patient-reported outcome 
measures (AOFAS, ATRS, Leppilahti, return-to-sport) via the online data management 
system (www.empowerhealthresearch.ca).  
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Chapter 5  
5 Results 
5.1 Participant Flow  
The flow of patients through each stage of the study is outlined in Figure 13. Between 
February 2014 and June 2015, 74 patients were screened for eligibility. Of these, 42 did 
not meet the eligibility criteria and eight declined to participate. We excluded patients if 
they presented to clinic at their baseline visit greater than seven days post-rupture (n=39), 
were greater than 70 years of age (n=2), or were diabetic (n=1). Patients declined to 
participate in the study because they did not want to receive an injection (n=3) and 
because they were unable to commit to all follow-up appointments (n=5). A protocol 
deviation occurred for one patient who was greater than seven days post-rupture at the 
baseline visit but was enrolled in the trial. A total of 24 patients were included in our 
randomized control trial. One patient was lost to follow-up at the one year visit because 
he moved to a different province.  
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Assessed for Eligibility (n=74) 
Enrolled (n=24) 
Included in this Thesis (n=20) 
ACP (n=10) 
Baseline (n=10) 
2 Weeks (n=10) 
4 Weeks (n=10) 
6 Weeks (n=10) 
8 Weeks (n=10) 
12 Weeks (n=10) 
24 Weeks (n=10) 
Included in Analysis (n=10)  
Non-ACP (n=10) 
Baseline (n=10)  
2 Weeks (n=10) 
4 Weeks (n=10) 
6 Weeks (n=10) 
8 Weeks (n=10) 
1 missing US (LOCF) 
12 Weeks (n=10) 
1 missing AOFAS, ATRS, 
ROM (LOCF) 
24 Weeks (n=10) 
Included in Analysis (n=10)  
Ineligible (n=50) 
     Age >70 (n=2) 
     Diabetes (n=1) 
     Rupture >7 days from initial visit (n=39) 
     Did not want injection (n=3) 
     Unable to commit to follow-up appointments (n=5) 
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Figure 12 Participant flow through the trial 
5.2 Demographic Information  
At the time of analysis, 20 patients had completed the study protocol to six months of 
follow-up. Patient demographic characteristics were similar between groups (Table 4). 
 
Characteristics  ACP® (n=10) Non-ACP® (n=10) 
Sex, n (%)                           
Male  
 
8 (80) 
 
8 (80) 
Median Age (IQR), years 39.0 (29.0 to 61.0) 38.0 (33.0 to 46.0) 
Median Height (IQR), cm 177.8 (171.4 to 181.6) 174.0 (165.1 to 180.7) 
Median Weight (IQR), kg 80.7 (75.0 to 91.8) 87.0 (71.8 to 93.2) 
Injured Achilles, n (%) 
Right  
 
5 (50) 
 
3 (30) 
Injured Achilles, n (%)                                 
Dominant  
 
6 (60) 
 
6 (60) 
Activity at injury, n (Sports 
or ADL) 
 
10 (Sports) 
 
10 (Sports)  
Abbreviations: IQR = Inter-quartile range; ADL = activities of daily living 
Table 4 Patient demographics 
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5.3 Injection Information  
White blood cell (WBC) and platelet quantification was conducted on both blood and 
ACP® samples from nine patients at baseline and at two weeks. One patient was missing 
WBC and platelet quantification on the ACP® sample at baseline because there was an 
insufficient amount of the sample to conduct the analysis (Table 5). 
 
Time 
Blood WBC 
Count*            
(mean ± SD) 
Blood 
Platelet 
Count*       
(mean ± SD) 
ACP® WBC 
Count*     
(mean ± SD) 
ACP® 
Platelet 
Count*  
(mean ± SD) 
Amount 
Injected‡ 
(mean ± SD) 
Baseline 7.7 (1.8) 215.1 (16.9) 0.9 (0.8) 390.7 (41.2) 3.2 (0.4) 
2 Weeks 6.9 (1.6) 232.2 (32.9) 0.8 (1.0) 441.6 (76.3) 3.1 (0.2) 
Abbreviations. WBC = white blood cell; ACP = Autologous Conditioned Plasma; SD = 
standard deviation               
*cell count x109/L                               
‡cubic centimeters (cc’s) 
Table 5 White blood cell and platelet counts of patients' blood and ACP samples 
5.3.1 “PAW” Classification  
Based on the classification system proposed by DeLong et al (2012)7, our ACP® system 
would be classified as “P2-Bβ”. “P2” represents a platelet concentration that is above 
baseline and up to 750 x 109 platelets/L. “B” and “β” represent below baseline 
concentrations of WBC and neutrophils, respectively.  
70 
 
 
 
 
 
5.4 Location of Tendon Rupture  
Tendon ruptures occurred at a mean of 5.2 cm (± SD 1.3 cm) from the calcaneal insertion 
as measured by baseline US assessments.  
5.5 Primary Outcome  
5.5.1 Estimated Percent Healing 
One patient in the non-ACP® group was missing eight week ultrasound data. There were 
no statistically significant differences between groups in the estimated percent healing at 
any time for US or MRI assessments. The mean rankings were higher in the ACP group 
versus the non-ACP group at 4 weeks (11.0 versus 10.0), 8 weeks (11.2 versus 9.8), and 
12 weeks (11.85 versus 9.15) for ultrasound assessments. The mean rankings were equal 
at 24 weeks. The mean rankings were higher in the ACP group at 12 weeks (12.6 versus 
8.4) and 24 weeks (11.4 versus 9.6) for MRI assessments. Figures 13-18 present the 
number of patients in each group that correspond to each healing range for both US and 
MRI at each time point.  
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Figure 13 Estimated percent healing at two weeks post injection with ACP or saline 
based on ultrasound imaging  
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Figure 14 Estimated percent healing at four weeks post injection with ACP  or saline 
based on ultrasound imaging 
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Figure 15 Estimated percent healing at six weeks post injection with ACP or saline based 
on ultrasound imaging (left) and MRI (right)  
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Figure 16 Estimated percent healing at eight weeks post injection with ACP or saline 
based on ultrasound imaging 
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Figure 17 Estimated percent healing at 12 weeks post injection with ACP or saline based 
on ultrasound imaging (left) and MRI (right) 
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Figure 18 Estimated percent healing at 24 weeks post injection with ACP or saline based 
on ultrasound imaging (left) and MRI (right) 
5.5.1.1 US and MRI Agreement  
5.5.1.1.1 Estimated Percent Healing  
The agreement between US and MRI ratings of healing was “fair” at 6 and 12 weeks, and 
“poor” at 24 weeks (Table 6).  
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Test Agreement (95% CI) 
 6 Weeks 12 Weeks 24 Weeks 
Weighted Kappa 0.20 (-0.06 to 0.46) 0.36 (0.03 to 0.68) 0.17 (-0.10 to 0.43) 
Abbreviations. CI = confidence interval. Note: According to Altman (1999)155 (slightly 
adapted from Landis & Koch (1977)156), agreement is classified as ‘poor’ if κ <0.20, ‘fair 
if κ > 0.20 to 0.40, ‘moderate’ if κ > 0.40 to 0.60, ‘good’ if κ > 0.60 to 0.80, and ‘very 
good’ if κ > 0.80 to 1.00.   
Table 6 Ultrasound and MRI agreement on ordinal ratings of estimated percent healing at 
6, 12, and 24 weeks  
5.6 Secondary Outcomes  
5.6.1 Patient-Reported Outcomes  
There was one patient in the non-ACP® group who did not complete the 12 week 
AOFAS and ATRS questionnaires. The ACP® group had higher median AOFAS change 
scores at six weeks and higher median ATRS change scores at 12 and 24 weeks. There 
was no significant difference in the median change scores from baseline at any time point 
for the AOFAS or the ATRS outcome measures. Both groups had improved change 
scores at each successive visit. There was a statistically significant difference in favor of 
the ACP group at 24 weeks for the Leppilahti score (p=0.04) (Table 7).  
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Time Outcome ACP® 
Median (IQR) 
Non-ACP® 
Median (IQR) 
p-value 
6 weeks 
AOFAS 32.0 (21.5 to 38.5) 29.0 (23.8 to 36.3) 0.80 
ATRS 12.0 (5.5 to 22.8) 19.5 (10.5 to 32.0) 0.44 
12 weeks 
AOFAS 38.0 (26.0 to 56.3) 40.5 (37.0 to 50.5) 0.85 
ATRS 38.0 (15 to 47.5)  32.0 (19.3 to 40.3) 0.28 
24 weeks 
AOFAS 45.5 (38.3 to 60.0) 48.5 (36.8 to 55.3) 0.63 
ATRS 66.5 (48.0 to 78.0) 61.0 (37.5 to 80.0) 0.74 
Leppilahti 75.0 (61.3 to 80) 55.0 (42.5 to 71.3) 0.04 
Abbreviations. ACP® = Autologous Conditioned Plasma; AOFAS = American 
Orthopedic Foot and Ankle Society; ATRS = Achiles Tendon Total Rupture Score; IQR 
= Interquartile range (25% to 75%) 
Table 7 American Orthopedic Foot and Ankle Society score, Achilles Tendon Total 
Rupture Score at 6, 12, and 24 weeks and Leppilahti score at 24 weeks post-rupture 
5.6.2 Functional Outcomes  
5.6.2.1 Range of Motion  
One patient in the non-ACP® group was missing ROM data at 12 weeks. The ACP® 
group had a lower median side-to-side deficit in plantar flexion at 6 and 24 weeks, and a 
lower median side-to-side deficit in dorsiflexion at 12 and 24 weeks. There was a 
statistically significant difference in the median side-to-side difference in dorsiflexion 
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ROM at 12 and 24 weeks in favor of the ACP®. Additionally, the ACP® group had a 
lower deficit in median calf circumference at 6 and 24 weeks. There were no statistically 
significant differences in plantar flexion or calf circumference between groups at any 
time point (Table 8). 
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Time Measurement 
(unit) 
ACP® Median 
Difference* (IQR) 
Non-ACP® Median 
Difference* (IQR) 
p-value 
6 weeks 
PF° 5.5 (-1.8 to 19.3) 13.5 (4.5 to 18.3) 0.35 
DF° 5.0 (0.0 to 9.5) 5.0 (3.8 to 10.8) 0.48 
CC (cm) 1.0 (0.8 to 3.3) 2.5 (2.0 to 3.0) 0.28 
12 weeks 
PF° 5.5 (0.5 to 7.0) 4.5 (3.8 to 9.8) 0.63 
DF° 3.5 (-0.3 to 5.0) 6.0 (5.0 to 8.0) <0.01 
CC (cm) 1.5 (-0.3 to 2.5) 1.5 (0.8 to 4.0) 0.63 
24 weeks 
PF° 2.0 (-1.0 to 4.5) 5.0 (2.0 to 8.3) 0.16 
DF° 1.5 (-2.8 to 3.3) 6.5 (4.5 to 7.5) <0.01 
CC (cm) 1.5 (1.0 to 2.0) 2.0 (0.8 to 2.0) 0.91 
Abbreviations. ACP® = Autologous Conditioned Plasma; PF = plantar flexion; DF = 
dorsiflexion; CC = calf circumference; cm = centimeters; IQR = Interquartile range (25% 
to 75%) 
Table 8 Range of motion and calf circumference measurements at 6, 12, and 24 weeks 
post-rupture 
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5.6.2.2 Isokinetic Plantar Flexion Strength 
There were no statistically significant differences between groups at any speed at 24 
weeks post-rupture for the median strength ratio of the injured to uninjured Achilles, as 
measured by the peak torque at each speed. The ACP® group had higher strength ratios 
at 30°/s and 240 °/s (Table 9).  
 
Speed 
(°/s) 
ACP® Median Strength Ratio 
% (IQR) 
Non-ACP® Median Strength Ratio 
% (IQR) 
p-value 
30 75 (55.8 to 83.8) 71.5 (57.5 to 90.5) 0.97 
60 70.5 (62.5 to 85.0) 73.0 (58.5 to 91.0) 0.85 
240 90.0 (70.3 to 106.3) 84.5 (61.8 to 93.8) 0.25 
Abbreviations. ACP® = Autologous Conditioned Plasma; IQR = 25% to 75% 
Interquartile range 
Table 9 Isokinetic strength ratio of the injured to uninjured Achilles at 24 weeks post-
rupture 
5.7 Re-Ruptures and Adverse Events 
There were no re-ruptures or adverse events for any patients in either group.  
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6 Discussion  
The purpose of this thesis was to compare the six month results for AT rupture patients 
who were randomized to receive ACP® or saline injections at baseline (i.e. within seven 
days) and two weeks post-rupture. Tendon healing was assessed using a longitudinal 
series of US and MR images. Functional assessments included isokinetic strength and 
ROM. Quality-of-life, pain, calf circumference, and subjective function was also 
assessed. We found a statistically significant difference in favor of the ACP® group at 24 
weeks for the Leppilahti score; there were no other significant differences between 
groups at any time point for any other outcome measures. However, it should be noted 
that our study was not powered to detect statistically significant differences. The aim of 
this study was not to make clinical recommendations but rather to determine whether a 
larger RCT is warranted.   
Slow tissue turnover and regeneration in the AT results in a lengthy return of normal 
function for patients with AT rupture. It has been demonstrated that non-operative 
management of AT ruptures can yield comparable results with respect to function and re-
rupture rates to operative management when early mobilization (i.e. accelerated 
functional rehabilitation) is employed4,5. The use of PRP to augment non-operative 
treatment to improve healing and function is a sound theory from a physiological 
perspective, although clinical benefits have yet to be conclusively demonstrated.  
In 2014, Kaniki et al8 prospectively recruited patients (n=73) with AT ruptures and 
injected them with ACP® within 14 days post-rupture, followed by a second injection 
two weeks later. The clinical and functional outcomes of these patients were compared to 
a retrospective cohort of non-operatively treated patients who did not receive ACP®. 
There were no significant differences between the ACP® group and the historical control 
group for isokinetic strength, ROM, or Leppilahti scores. One potential explanation for 
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the lack of a treatment effect is that the injection period for patients in the ACP® group 
corresponded to the mid- to late-proliferative (or reparative) phase of tendon healing 
rather than the inflammatory phase of tendon healing. A significant characteristic of the 
inflammatory phase of tendon healing is the activation of platelets at the site of 
injury14,15. It was therefore hypothesized that ACP® injection during this early phase of 
healing may have a more pronounced effect.  
Our results demonstrate slightly more favorable assessments of healing in the ACP® 
group at 4, 8, and 12 weeks on US and at 12 and 24 weeks on MRI. Furthermore, the 
secondary outcomes in our study tended to favor the ACP® group over the non-ACP® 
group: the median ATRS was higher at 12 and 24 weeks; the median Leppilahti score 
was significantly higher at 24 weeks; the median side-to-side ROM differences were 
smaller in plantar flexion at 6 and 24 weeks and in dorsiflexion at 12 and 24 weeks; and 
the isokinetic strength ratio was larger at 30°/s and 240°/s. 
One of the issues in the published literature that has made it difficult to draw definitive 
conclusions about the effectiveness of PRP is that most studies do not report the 
concentration of the components of the PRP used or the preparation method. Without 
accurate documentation of the concentration of platelets, the manner of platelet 
activation, and the presence or absence of WBCs the ability to truly contextualize study 
results is limited7. DeLong et al (2012)7recently provided a means to classify solutions of 
PRP (Figure 8). According to this classification system, the PRP samples prepared for 
this study (i.e. ACP®) is “P2-Bβ” which means that the concentration of platelets is 
greater than baseline but less than 750x109 /L (P2), the WBC concentration is below 
baseline (B), and the neutrophil concentration is below baseline (β).  A sample of PRP 
that is too concentrated in platelets (i.e. >1800x109) can potentially have a toxic effect, 
resulting in cellular apoptosis, growth factor receptor downregulation, and receptor 
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desensitization, which ultimately may result in a paradoxical inhibitory effect157,158. PRP 
samples above baseline and less than 750x109 /L have produced favorable results in 
several studies12,159–165. The presence of WBC and neutrophils above baseline levels in 
PRP samples has been linked to deleterious effects during tissue regeneration166–172, thus 
our preparation method sought to avoid this potential issue by limiting their presence in 
our samples.  
Several studies have described the US or MRI features of an acutely ruptured or healing 
Achilles tendon56,61,81,88,89, but none have used imaging to provide an overall estimation 
of healing in the tendon. Furthermore, no other study has evaluated the tendon during the 
different phases of tendon healing:  Hollenberg et al61 described the US appearance of 
ruptured ATs treated non-operatively within 48 hours of rupture and again at 
approximately two years; Möller et al81 described and evaluated the healing AT following 
surgery using US and MRI after 6, 12, and 24 weeks; Karjalainen et al88 evaluated the AT 
3, 6, 12, and 24 weeks post-surgery using MRI. Our study evaluates the non-operatively 
treated AT within seven days of rupture (inflammatory phase), and at 2 (proliferative 
phase), 4 (proliferative phase), 6 (proliferative/remodeling phase), 8 (remodeling phase), 
12 (remodeling phase), and 24 (remodeling phase) weeks post-rupture, ultimately 
spanning all phases of the healing process.  
Physiologically, the inflammatory phase is characterized by fluid infiltration causing 
edema and subsequent activation of platelets and inflammatory cells13–15. On US 
imaging, the fluid infiltration can be seen as an anechoic area located at or near the 
rupture site. Additionally, there was marked loss in the normal fibrillar architecture of the 
tendon (Figure 19).  During the proliferative or reparative phase, tendon fibroblasts have 
begun collagen synthesis and deposition into the wound site14,15. On US, collagen and 
other extracelluar matrix components (collectively termed ‘granulation tissue’) appeared 
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echogenic (i.e. bright) relative to the tendon (Figure 20). Similarly, on most MR 
sequences, granulation tissue appears as increased signal intensity relative to the normal 
tendon (Figure 21).  The remodeling phase is characterized by the transformation of 
granulation tissue to fibrous tissue, and again to scar-like tissue with high tensile 
strength14,15. There is decreased cellularity and fluid presence at and around the injury 
site. Scar tissue appeared hypoechoic to the surrounding tissue on US (Figure 22), and 
hypointense on MRI (Figure 23). Disruption of the normal fibrillar architecture was 
evident at 24 weeks post-rupture is a well-documented finding on US as described in 
previous studies56,61,81Additionally, tendon thickening is evident on both US and MRI 
also described in previous studies61,81,88,89.  
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Figure 19 Baseline US of an acute Achilles tendon rupture (inflammatory phase). Long 
axis view at the rupture site shows discontinuity of tendon fibres (T) with a gap (arrows 
demarcate proximal and distal ends of the torn fibres) and a small anachoic fluid 
collection (*) likely related to a hematoma. The Torn tendon fibres are hypoechoic, 
mildly redundant and show loss of the normal fibrillar pattern 
Long Axis
T
T
*
Proximal
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Figure 20 Ultrasound image at six weeks (proliferative phase) in the same patient as 
Figure 19. The previous anechoic fluid collection at the tear site has resorbed. A 
prominent gap is evident at the site of the tear (arrows) filled with echogenic tissue (*) 
which may correspond to granulation tissue. The tendon fibres adjacent to the tear are 
thickened, disorganized and hypoechoic, potentially corresponding to persistent edema 
and/or fibrous tissue  
Long AxisProximal
T T
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Figure 21 MR image at six weeks (same patient). Sagittal fast inversion recovery image 
(water weighted) shows a complete tear of the Achilles tendon with a residual gap at the 
site of the tear (arrow) marked by increased signal intensity. Increased fluid manifested 
by high signal intensity likely corresponding to extensive edema is present, most 
conspicuous within the proximal aspect of the tendon (*).  
T
T
*
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Figure 22 Ultrasound image at 24 weeks (late remodeling phase). Panorama long axis 
ultrasound. The Achilles tendon (T) is thickened, hypoechoic with mild redundancy, loss 
of the normal fibrillar pattern and disorganization of the tendon fibres, likely reflecting 
post-traumatic scarring due to extensive background microtearing. There is slightly 
increased signal at the site of previous discrete tear (arrows), without a residual gap 
evident.  
CalcaneusT
T
Proximal Long Axis
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Figure 23 MR image at 24 weeks (late remodeling phase). Sagittal fast inversion 
recovery (water weighted). The previous gap is even more inconspicuous filled with 
hypointense/dark tissue (*), likely corresponding to fibrous tissue. The tendon remains 
thickened and abnormal  
Ruptures of the AT occurred at a mean of 5.2 cm from the calcaneal insertion. Similarly, 
Karjalainen et al88 and Hollenberg et al61 reported rupture sites at a mean of 5.9 cm and 6 
cm from the calcaneal insertion, respectively. In a cadaveric study, Carr et al173 reported 
that there is an area of low vascularity most prominent between 2 and 4 cm from the 
calcaneal insertion. In our series, few patients had ruptures below this region and 
therefore our results are in accordance with Schmidt et al174 and Karjalainen et al88 who 
*
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stated that the area of poor vascularization and the rupture site may not necessarily be 
correlated. 
The agreement between US and MRI in our study at coinciding time points was 
considered “fair” at 6 and 12 weeks (κ=0.20 and κ=0.36, respectively) and “poor” at 24 
weeks (κ=0.17) according to the guidelines proposed by Altman (1999)155.  This 
agreement was considerably lower than the agreement reported by Connell et al94 
(κ=0.52) in the MR and US evaluation of hamstring tears after six weeks. The most likely 
explanation for poor agreement is our small sample size. Discrepant assessments of 
healing between MRI and US have a pronounced effect on a small sample size compared 
to a large sample size, especially in cases of extreme disagreement (i.e. ratings that differ 
by two or more ordinal categories on a four category scale). Another potential 
explanation is that we injected patients with either ACP® or saline, ultimately increasing 
the amount of fluid at the injury site. This would likely present similarly to fluid/edema 
on both MRI and US. Fluid is easier to distinguish from fibrous tissue on MRI than US. 
On US both fluid and fibrous tissue appear hypoechoic, making distinction between the 
two sometimes difficult. On MR however, fluid or edema appears as increased signal 
intensity whereas fibrous tissue would appear as low signal intensity relative to the 
healthy tendon. It has been shown that edema can be present in healing ATs up to six 
months post-rupture81, therefore a discrepancy between US and MRI as a result of 
distinguishing fluid from fibrous tissue could have occurred at all time points in our 
study.  
6.1 Study Strengths  
Strengths of our study include the randomization of patients to intervention and control 
groups, reducing the chance of selection bias. We were also able to blind the patient, 
clinician, radiologist and outcome assessor to group allocation, reducing expectation and 
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performance biases. We also only lost one patient to follow up (5%) and only two 
patients had missing or incomplete data (10%). To our knowledge, our study is the first 
RCT for PRP in the non-operative management of AT ruptures. Additionally, our study is 
the first to attempt to quantify healing based on US and MR imaging.  
6.2 Study Limitations  
Our study was limited by a small sample size that limited our power to detect a 
statistically significant treatment effect. Although we were aware we would be 
underpowered, the small sample size led to a non-parametric distribution of data with 
prevented us from performing parametric statistical analyses.  
Our primary outcome was not a valid or reliable outcome measure, as we are the first to 
attempt to quantify tendon healing based on imaging. Although there are objective 
criteria that are evaluated within each tendon image, the overall estimation of percent-
healing is subjective to the radiologist interpreting the image. Furthermore, the 
radiologist was not blinded to the time-point of each image post-rupture, so it is possible 
that there was an observational bias whereby the number of weeks post-rupture could 
have influenced the healing rating. However, the radiologist was blinded to group 
allocation so any observational biases would have been equal between groups and thus 
should not have had a directional influence on the results.  
7 Conclusion 
This study compared the healing and function in non-operatively treated AT rupture 
patients receiving either ACP® (n=10) or saline (n=10) injections. The findings in this 
study are underpowered but there is sufficient evidence to suggest moving forward with a 
larger RCT for early ACP® injections.  
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7.1 Directions for Future Research 
A. We will continue data collection for one-year functional (isokinetic strength, 
ROM) and patient-reported (AOFAS, ATRS, Leppilahti) outcomes for all 
remaining patients.  
B. Further study into the use of different classifications of PRP (i.e. different 
concentration of platelets, different method of platelet activation) to determine if 
this will yield more favorable results.  
C. Further study into whether certain features of AT imaging are predictive of, or 
correlated to clinical or functional outcomes 
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Appendix D: MR Imaging Sequences 
Protocol  Field of 
View  
TR, TE, 
(TI) 
Echo 
Train 
Length  
Slice 
Thickness, 
Spacing  
Matrix 
(Frequency 
& Phase) 
Number of 
Excitations  
Sagital 
fast-spin 
echo T1 
20 cm  700 ms, 15 
ms 
2 3.5 mm, 0.5 
mm  
385 x 224 1 
Sagital 
fast-
recovery 
fast-spin 
echo T2 
20 cm  3000 ms, 
70 ms 
12 3.5 mm, 0.5 
mm 
320 x 224 2 
Sagittal 
3D proton 
density 
CUBE 
20 cm  3000 ms, 
minimum  
 
64 0.7, 0 192 x 192  0.5  
Sagittal 
fast 
inversion 
recovery  
20 cm  4250 ms, 
34 ms, 
(150 ms) 
8 3.5 mm, 0.5 
mm  
245 x 224  2 
Axial fast-
spin T2 
14 cm  4000 ms, 
70 ms  
15 4 mm,  
0.5 mm  
320 x 224  1 
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